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Since its approval by the FDA in 1978 cisplatin (cis-
diamminedichloroplatinum(II)) has revolutionized the treatment of several cancer types, 
particularly testicular cancer which now has a cure rate greater than 90%. Following the 
example set by its success, a broad range of antitumor metallodrugs is being developed. 
One of the most promising of these drugs, currently in Phase Two of clinical trials, is the 
Ru-based NAMI-A (imadozolium trans-
[tetrachloro(dimethylsulfoxide)(imidazole)ruthenate(III)]) which displays low systemic 
toxicity and strong antimetastatic activity. The majority of anticancer metallodrugs 
(including NAMI-A and cisplatin) can bind to DNA, which, in many cases, is an 
important therapeutic target. Much effort has gone into characterizing the DNA binding 
properties of anticancer metallodrugs. Less study has gone into characterizing the 
interaction of anticancer mellodrugs with RNA even though RNA is chemically similar to 
DNA and plays important roles in gene expression and regulation. Focusing on the 
  
 
 
v 
extensively studied cisplatin, Chapter I covers both what is known about anticancer 
metallodrug-RNA binding and the information that can be gleaned from DNA binding 
and drug localization studies. Chapter II provides the details of a kinetic investigation of 
the in vitro binding of aquated cisplatin to an RNA sequence containing an internal loop 
derived from the core of the spliceosome, a related RNA hairpin, and the slower reacting 
DNA hairpin analog. Chapter III follows in cellulo studies with cisplatin-treated S. 
cerevisiae that demonstrate, using ICP-MS, differences in Pt accumulation in mRNA and 
rRNA. The effects of cisplatin treatment on S. cerevisiae cell growth and viability were 
investigated using clonogenic and morphologic assays. In Chapter IV the same protocols 
were applied in order to investigate Ru accumulation on RNA following S. cerevisiae 
treatment with NAMI-A. These in cellulo experiments were followed by in vitro binding 
studies that utilized MALDI-MS to compare Ru interactions with RNA and DNA 
oligonucleotides following treatment with NAMI-A under different solution conditions, 
finding enhanced binding in an acidic, reducing environment like that found in tumor 
tissue. Chapter V pulls together the knowledge gained so far and discusses questions for 
future investigation. 
This dissertation includes both previously published and unpublished coauthored 
material.  
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CHAPTER I 
INTRODUCTION 
 
This dissertation focuses on the effects of cisplatin and NAMI-A treatment on 
RNA both in vitro and in cellulo in order to gain insight into the binding of anticancer 
metallodrugs to RNA. The ultimate aims of this project are to gain information towards 
the elucidation of the roles that RNA plays in the mechanisms of anticancer metallodrugs 
and the development of a fundamental understanding of the ways that RNA can be 
targeted and impacted by metal based drugs. Chapter I gives an overview on what is 
known about the interaction of anticancer metallodrugs with RNA, focusing on cisplatin 
as it is the best studied anticancer metallodrug. It includes material adapted from: 
Chapman, E. G.; Hostetter, A. H.; Osborn, M. F.; Miller, A. L.; DeRose, V. J. “Binding 
of Kinetically Inert Metal Ions to RNA: The Case of Pt(II)” In Metal Ions in Life 
Sciences: Structural and Catalytic Roles of Metal Ions in RNA; Royal Society of 
Chemistry: Cambridge, UK, 2011; in press – Reproduced by permission of The Royal 
Society of Chemistry. This material was co-written and co-edited by me, Dr. Erich G. 
Chapman, Maire F. Osborn, and Amanda L. Miller with guidance and editing by Prof. 
Victoria J. DeRose. The material included in Chapter I from the above publication is 
taken from sections in which I had significant input.  
Chapter II covers kinetic studies comparing the platination rate of cisplatin-treated 
RNA and DNA oligonucleotides, mapping experiments that localized the platinum 
binding sites, and MALDI-MS data that demonstrate the stoichiometry of the platinated 
products. It includes previously published coauthored material with contributions from 
 2 
 
Dr. Erich G. Chapman and Prof. Victoria J. DeRose. Chapter III follows in cellulo studies 
of cisplatin-treated S. cerevisiae in which Pt accumulation in yeast RNA was quantified 
by ICP-MS, the effects of cisplatin treatment on S. cerevisiae were examined using 
growth and clonogenic assays combined with DAPI and TUNEL staining. Specific 
platinum binding sites in ribosomes were located with mapping experiments. It includes 
coauthored material intended for publication with contributions from Maire F. Osborn 
and Prof. Victoria J. DeRose. Chapter IV covers in cellulo studies of NAMI-A treated 
yeast and in vitro MALDI-MS experiments comparing binding to RNA and DNA 
oligonucleotides under different solution conditions. It includes material submitted for 
publication with contributions from Michelle L. Miranda, Prof. Victoria J. DeRose, and 
Prof. Karen L. McFarlane Holman. Chapter V pulls together the knowledge gained so far 
and discusses questions for future investigation. 
 
Anticancer Metallodrugs 
Cisplatin (cis-diamminedichloroplatinum(II), Figure 1.1) was the first clinically 
used metal-based anticancer drug. Particularly effective in the treatment of testicular, 
ovarian, oropharyngeal, broncogenic, cervical, and bladder carcinomas, and lymphoma, 
osteosarcoma, melanoma, and neuroblastoma, cisplatin has had a profound effect in 
making many types of cancer more treatable. Currently cisplatin and two structurally 
related Pt(II) drugs (carboplatin and oxaliplatin, Figure 1.1) are used in the treatment 
regimes of 50-70% of cancer patients.1 However, both innate and acquired resistance 
limit the usefulness of these three drugs in other types of cancer, and cisplatin in 
particular has a high general toxicity that causes dose-limiting side effects. In addition, 
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while platinum anticancer drugs are highly active against primary tumors, they have 
limited activity against metastasis.2  
 
 
Figure 1.1. The structures of the three FDA-approved Pt antitumor drugs. 
 
Both the success and limitations of cisplatin have spurred a great deal of effort to 
develop other platinum-based anticancer drugs. Thousands of platinum drugs have been 
synthesized and evaluated, but only two (carboplatin and oxaliplatin) have made it to 
worldwide clinical acceptance.3 Carboplatin (cis-
diammine(cyclobutanedicarboxylato)platinum(II)) contains the same active Pt(NH3)2 
fragment as cisplatin and thus has the same mechanisms of action and resistance as 
cisplatin. However, carboplatin is less toxic than cisplatin, especially to the nervous 
system and kidneys.4 Oxaliplatin (cis-oxalato-(trans-1)-1,2-
(diaminocyclohexane)platinum(II)) also demonstrates lower toxicity than cisplatin and 
shows a lack of cross-resistance with cisplatin and carboplatin.3,4 Despite the advances 
made, these three platinum antitumor drugs all have major drawbacks relating side-
effects, intrinsic and acquired resistance,5 and low effectiveness against metastasis.6  
As a result of these limitations, studies have branched out and the anticancer 
properties of other transition metal drugs are being examined, including drugs based on 
ruthenium, arsenic, gallium, titanium, copper, iron, rhodium, and tin.5,7 Of the transition 
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metals tested, the ruthenium-based pharmaceuticals are one of the most promising groups 
and have attracted a great deal of attention due to their multiple accessible oxidation 
states, ability to mimic iron, and favorable ligand exchange kinetics (similar to those of 
platinum). These properties have the potential to provide lower general toxicity, selective 
accumulation in tumor cells, selective activation by reduction within the tumor 
microenvironment, a different mechanism of action, and antimetastatic activity.8 A 
prominent example of the Ru-based anticancer drugs is NAMI-A (imadozolium trans-
[tetrachloro(dimethylsulfoxide)(imidazole)ruthenate(III)], Figure 1.2), a drug which is 
currently in Phase Two of clinical trials. NAMI-A exhibits low general toxicity, strong 
antimetastatic activity, and an alternate mechanism of action. It is one of the best studied 
Ru-based anticancer metallodrugs.8  
 
 
 
Figure 1.2. The structure of NAMI-A. 
 
A feature common to the majority of transition metal-based anticancer drugs, 
including the platinum and ruthenium-based drugs, is an ability to bind to DNA. In many 
cases DNA is considered to be an important therapeutic target for drug activity.7,3 This is 
certainly the case for cisplatin, which is the most thoroughly studied metal anticancer 
drug.2 Although chemically similar to DNA, the RNA-binding of metal based anticancer 
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drugs is rarely tested, despite the importance of RNA in gene expression and 
regulation.9,10 This is a gap that the work presented in this dissertation aims to address. 
Two broad, overarching goals guide this work. The first goal is to elucidate the role that 
RNA plays in the mechanisms of anticancer metallodrugs. The second is to gain insight 
into binding of metallodrugs to RNA in order to build a fundamental understanding of the 
ways that RNA can be targeted and impacted by drugs, whether they are metal-based or 
not. Since little is currently known, the studies presented here use cisplatin and NAMI-A 
to answer some basic questions about metallodrug-RNA binding in order to lay a 
foundation for future studies. This chapter will provide background on what is currently 
known, focusing on Pt(II) drugs, and cisplatin in particular, because they are the best 
studied anticancer metallodrugs and their nucleic acid binding properties have been 
elucidated in detail for DNA. First, an overview of cisplatin’s mechanism of therapeutic 
action is given. In order to gain insight into what might be expected for RNA, both the 
solution chemistry of cisplatin and the DNA binding modes of its aquated species are 
examined. This is followed by a discussion about RNA as drug target. Next, the studies 
that have been done so far on the effect of cisplatin treatment on RNA and RNA-
dependent processes are investigated. In order to gain an understanding of how Pt drugs 
may interact with RNA in a cellular context, studies on the types of biomolecules 
targeted by Pt(II) drugs in cellulo will be examined, followed by a discussion of in cellulo 
Pt(II) drug localization studies which may give an indication of the RNA species and 
processes that are likely targets of platinum drugs. Finally, both the solution chemistry of 
NAMI-A and the effects of NAMI-A treatment on DNA will be examined in order to 
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provide context for in vitro and in cellulo studies on the effects of NAMI-A treatment on 
RNA.  
 
Cisplatin 
Cisplatin is the best-studied anticancer metallodrug and, although there still are 
features of its mechanism of action that are not understood, many aspects of its solution 
chemistry, DNA binding, and biochemistry have been worked out. It is administered to 
patients intravenously. The two NH3 ligands are kinetically inert. In the bloodstream the 
high concentration of chloride (100 mM) prevents the two labile chloride ligands from 
aquating. Upon entering a cell, through either passive diffusion or active transport, the 
lower chloride concentration present (4-12 mM) induces aquation to either the monoaqua 
or the diaqua form.2 These cationic aqua derivatives are the biologically active forms 
which bind to ‘soft’ nucleophilic targets including the cysteine, methionine, and histidine 
residues on proteins, and the N7 site on guanine and adenine bases. Since cisplatin has 
two open coordination sites, the majority of the final platinated products formed are 
bifunctional cross-links.  
On DNA the major products are intrastrand cross-links which distort the DNA 
backbone, resulting in pinching of the major groove and a widening of the minor grove. 
Multiple classes of proteins recognize this altered DNA structure, and it is believed that 
this recognition causes a series of cellular events which ultimately lead to cell cycle arrest 
at the G2 phase and the induction of apoptosis; many pieces of this mechanism, however, 
are not yet fully understood.11 In addition, while intrastrand DNA adducts are known to 
inhibit transcription and replication, cisplatin treatment can also inhibit splicing and 
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translation in extracts.12,13 As discussed below the nucleolus is a particular is target for 
platinum accumulation, and rRNA biogenesis, splicing, and mRNA maturation all take 
place there, making it likely that some of these processes will be disrupted.  
 
Cisplatin Solution Chemistry and DNA Coordination 
Since cisplatin is activated by aquation, a large number of studies have been done 
on cisplatin aquation in at wide range of different pH values, temperatures, and buffer 
conditions.14 One of the studies that used solution conditions that were more biologically 
relevant than other studies was a NMR study by Daves et al. of 1.51 mM cisplatin at 25 
ºC, pH 5.9, in 9 mM NaClO4.15 Scheme 1.1 shows the aquation of cisplatin. The rate 
obtained for the first step of cisplatin aquation is 2.38 (4) × 10-5 s-1, while the anation rate 
(the rate of replacement of the water ligand with the chloride anion) is 4.6(3) × 10-3 M-1  
s-1. The rate constant for the aquation of the monoaqua species is 1.4(3) × 10-5 s-1, and the 
anation rate is 81(22) × 10-3 M-1s-1. In both cases the chloride-dependant anation rate is at 
least two orders of magnitude larger than the aquation rate. Based on this, it is clear why 
the concentration of chloride ion is critical to activation of cisplatin inside the cell.16 It is 
worth noting that the measured half-life of cisplatin aquation ranges from 2-8 h 
depending on the solution conditions used, with 2 h being a generally accepted 
number.2,14,15 The pKa’s of each of these species is shown in Scheme 1.1.17 At neutral 
biological pH 7.4 (healthy tissue) we would expect to get a mixture of these species, with 
significant amounts of the less reactive hydroxo species, but at pH 6.0 (tumor tissue)18 the 
majority of the species will be in the more reactive aqua forms.19 
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Scheme 1.1. The aquation of cisplatin with the pKas of the various aqua species shown. 
The pKa values were taken from 17. 
 
Once formed, the cationic Pt(II) aqua species enter the condensed cationic 
atmosphere surrounding the polyanionic nucleic acid.20-23 Here they may form transient 
associations with the negatively charged phosphodiester backbone before forming 
kinetically inert bonds to guanine and adenine N7 sites, forming first a monoadduct 
which then closes to form the diadduct. Because the bonds formed to the nucleobases are 
kinetically inert, binding with them by Pt(II) is under kinetic, rather than thermodynamic, 
control.2 In addition, because the initial aquation of cisplatin is so slow, aquation is the 
rate-limiting step for reaction with DNA in vivo.17 For this reason kinetic studies 
comparing the reaction rates with different targets, such as RNA or different DNA 
structures, use either [Pt(NH3)2Cl(OH2)]1+ or [Pt(NH3)2(OH2)2]2+ in their reactions rather 
than freshly dissolved cisplatin. 
The most common DNA adducts are 1,2 intrastrand cross-links, with 1,2-d(GpG) 
intrastrand cross-links accounting for 60-65% of adducts, and 1,2-d(ApG) intrastrand 
cross-links accounting for 20-25%, 1,3-d(GpNpG) intrastrand cross-links accounting for 
5-10%, and interstrand cross-links, DNA-protein cross-links, and monofunctional adducts 
being rare, but observed (Figure 1.3).24 The preference of guanine over adenine bases has 
 9 
 
been proposed to be due to both the more favorable orbital overlap between the cisplatin 
LUMO and the guanine HOMO (due to the lower energy of the guanine HOMO) and the 
ability of the NH3 ligand to form a hydrogen bond to the O6 keto oxygen of guanine.25 
Based on this, for RNA the same favoring of guanine over adenine would be expected. 
 
 
Figure 1.3. The main adducts formed upon treatment of DNA with cisplatin, from left to 
right: 1,2-d(GpG) intrastrand cross-link, 1,2-d(ApG) intrastrand cross-link, 1,3-
d(GpNpG) intrastrand cross-link, and interstrand cross-link.  
 
Many studies have been done on the influence of DNA structure on the rate of 
Pt(II) coordination. One study, of a DNA telomere quadruplex (a highly repetitive DNA 
sequence from the end of a chromosome capable of forming a four-stranded structure) 
with [Pt(NH3)2(OH2)2]2+ demonstrated that platination of the telomere proceeded at twice 
the rate of the double stranded DNA which in turn proceeded at three times the rate of the 
single stranded DNA.26 Several studies using the [Pt(NH3)2(OH2)2]2+ species have looked 
at the closure of the monoadduct (an adduct in which platinum is bound to the DNA at a 
single coordination site) to either a bifunctional intrastrand or interstrand adduct (adducts 
in which two coordination sites of the same Pt are bound to the DNA at different 
bases).The rate of this chelation from the monoadduct to the bifunctional adduct is quite 
variable based on sequence and structure. For single-stranded DNA a significantly faster 
rate of chelation to the 1,2-intrastrand adduct is observed than for double-stranded 
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DNA.27 In addition, the rate of closure to an interstrand cross-linked adduct is faster than 
1,2-intrastrand chelation.28 The effects of structure on closure rate shown here may mean 
that in RNA, where there is a much wider variety of structural motifs, a different set of 
adducts will be formed and that the structure of each RNA species will result in certain 
cross-links being kinetically favored. 
 
RNA as a Drug Target 
The field of RNA biology has grown considerably and there is increasing 
recognition of the importance of RNA-dependent cellular processes. In addition to well-
known functional roles in translation (mRNA, tRNA, and ribosomes) a great deal is now 
being learned about the regulatory roles carried out by RNAs such as siRNA, microRNA, 
piwi-interacting RNA, and long noncoding RNA in both transcription and translation.29 
This importance of RNA-based processes is reflected by the complexity, careful 
regulation of, and considerable resources invested in processes such as ribosome 
biogenesis.30 There is also a plethora of pathways that recognize and degrade damaged 
and non-functional RNA species, a number of which are only beginning to be elucidated. 
These degradation pathways include noncoding RNA decay,31 no-go decay,32 nonsense-
mediated decay,32 non-stop decay,32 nonfunctional ribosomal decay,33 and rapid tRNA 
decay.34 There have also been reports of enzymes that can repair RNA, including two 
human AlkB homologues that repair methylated purine lesions in both DNA and RNA in 
vitro and when expressed in E. coli.35 In addition, an activity has been reported in 
mitochondrial extract that can repair the 3’-ends of truncated tRNAs.36 When damaged 
RNA is not degraded or repaired there can be serious consequences. For example, RNA 
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oxidation is an early event involved in the pathogenesis of many neurodegenerative 
disorders including Alzheimer’s disease, Parkinson’s disease, Epilepsy, spinal cord 
injury, and amyotrophic lateral sclerosis.37  
At the same time that an understanding of the complexity and importance of RNA 
biology has been growing so has an understanding of the links between RNA and 
apoptosis, a type of programmed cell death typically exploited by anticancer drugs. The 
toxic proteins sarcin38 and ricin39 invoke apoptosis through their interaction with the 
sarcin/ricin loop of the large subunit of the eukaryotic ribosome. Proteins that play roles 
in both DNA repair and the decay of defective ribosomes have been discovered, coupling 
DNA and RNA surveillance mechanisms.40 Connections between ribosome biogenesis, 
control of the cell cycle, and the tumor suppressor protein p53 (which is thought to play a 
pivotal role in cisplatin-induced apoptosis) have also been found in which the ribosomal 
proteins can activate p53 in response to ribosomal stress such as the inhibition of rRNA 
transcription or the induction of the unfolded protein response in the endoplasmic 
reticulum.41-43 Disruption of rRNA processing and imbalances of the ribosomal protein 
pool can also activate p53.44   
In addition, RNA has been postulated to play specific roles within apoptosis. 
Stress in known to induce tRNA cleavage45 and rRNA is specifically degraded in 
response to apoptotic stimuli.46,47 It is possible that these specific degradation fragments 
may play a role in cell signaling. In addition, tRNA has been shown to inhibit apoptosis. 
It does this through binding to cytochrome c, a key mediator of the intrinsic apoptotic 
pathway that is released from the mitochondria and subsequently binds to and activates 
the caspase activator Apaf-1 (caspases are the effectors of apoptosis). The binding of 
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tRNA to cytochrome c inhibits cytochrome c binding to Apaf-1 and subsequent caspase 
activation both in vitro and in living cells.48  
 Taken together, it is clear that RNA processes have many important functions in 
the cell, that disruption of these processes can have serious consequences, and that there 
are links between RNA pathways and programmed cell death. Therefore RNA could be 
an important target of anticancer metallodrugs.  
 
Cisplatin and RNA  
Effect on RNA Processes 
A few studies have been done on both the effects of cisplatin treatment on RNA 
processes and the formation of specific Pt adducts on RNA. In cellulo studies have 
measured the effect of cisplatin treatment on replication, transcription, and translation 
through the incorporation of isotopically labeled nucleotides or amino acids in both S. 
cerevisiae and a human placental cell line.49,50 Inhibition of replication occurred at a 
slightly lower concentration than transcription or translation, but all processes are capable 
of being significantly inhibited by cisplatin.  
In vitro studies have examined the effects of cisplatin treatment on transcription, 
splicing, translation, and enzymatic RNA degradation (Figure 1.4). With the exception of 
certain RNA polymerase studies in which single platinum adducts were placed on DNA 
templates,49,51 these studies were all carried out in complex systems with both protein and 
RNA components. This means that in these complex systems the cisplatin treatment 
could interfere with any of the RNA structures, RNA protein interactions, or protein-
protein interactions. Ribosomal RNA transcription by RNA polymerase I has been shown 
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to be preferentially blocked in HeLa cells.52 Arrest of RNA polymerase II at platinum-
DNA lesions has been demonstrated in vitro,53 in extracts,51 and in cellulo54 in 
mammalian cells. This arrest is caused by the inability of the platinum-DNA lesion to 
enter the active site of the polymerase. In HeLa cell nuclear extract cisplatin treatment 
was shown to cause dose-dependent inhibition of splicing. This inhibition was judged to 
occur during the initial stages of spliceosome assembly on pre-mRNA.12 In addition, 
cisplatin treatment has also been shown to inhibit splicing in the protein-independent self-
splicing Tetrahymena rRNA, possibly through the formation of an interstrand cross-
link.55 
 
 
Figure 1.4. RNA processes inhibited by cisplatin treatment as determined by in cellulo 
and in vitro studies. References: a) 53, 54 b) 62 c) 55 d) 12 e) 66, 67 f) 61 g) 13, 56, 57 h) 
60. 
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Rabbit reticulocyte lysate has been used to study the effect of cisplatin on mRNA, 
the translation machinery, and the resulting protein synthesis. In work done by Rosenburg 
and Sato incubation of mRNA with cisplatin inhibited translation with an IC50 of 39 µM. 
Analysis of the peptide products showed greater inhibition of longer peptide sequences, 
indicating an obstruction of the elongation process.13,56 When the extracts themselves 
were incubated with cisplatin, inhibition of protein synthesis was observed, but to a lesser 
extent. There was also a decrease of polysome intensity. This decrease, combined with 
the biphasic kinetics of inhibition, matched the effects of NaF, an inhibitor of translation 
initiation. This was interpreted to mean that cisplatin treatment of the lysates caused 
inhibition of the translational machinery at initiation.13 A later study by Heminger and 
coworkers found a slightly different result. They observed a steady accumulation of 
higher order polysomes following cisplatin treatment, leading them to conclude that the 
translation machinery was inhibited at elongation, not initiation. However, the intensity 
of the polysome fractions appears to decrease following cisplatin treatment. Therefore it 
is likely that both effects are taking place.57    
RNA nucleases are important in the RNA processing machinery, as well as the 
RNA surveillance and degradation machinery.58,59 Platinum-RNA adducts have been 
shown to inhibit the activities of 5’-to-3’ and 3’-to-5’ exonucleases and purine-specific 
endoribonucleases in vitro.60 Primer extension by reverse transcriptase has also been 
shown to be inhibited by platinum adducts.60,61 
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Specific Pt Adducts Formed on RNA 
The formation of platinum adducts on RNA following cisplatin treatment has 
been studied kinetically on hairpin oligonucleotides, and mapped on hairpins, tRNA, and 
rRNA. The kinetics of the reaction of cis-[PtCl(NH3)2(OH2)]+ and two other platinum 
drugs with RNA and DNA hairpins was studied at pH 6.0 by Elmroth et al. using HPLC 
methodology.63 The RNA hairpin reacted ~ 2 fold faster than DNA and the rate of 
reaction between the Pt compounds and both RNA and DNA showed a significant 
dependence on the monovalent ion concentration, with decreased reaction rate at higher 
monovalent ion concentrations. This dependence was more pronounced for RNA than 
DNA.  
Early studies sought to identify platinum binding sites in tRNAPhe using pre-
formed crystals. Sundarlingham and coworkers identified two adducts in the D arm of the 
tRNA at relatively low 5.5Å resolution.64 Later, Dewan reported a 6Å structure with four 
platinated sites.65 Elmroth and coworkers have mapped platination sites in cisplatin 
treated tRNAPhe as well as models of the anticodon loop and acceptor stem.66,67 They 
found platinum binding at a G-C rich wobble basepair region in the acceptor stem that is 
critical for tRNA function. This binding is structurally sensitive and the binding pattern is 
altered by the introduction of a 5’-terminal phosphate and is inhibited by the replacement 
of the G•U wobble pair with a G-C base pair. Binding was also observed in the anticodon 
stem, where the substitution of a natural UG in the terminal loop with a GG increases the 
rate of platination alters the binding pattern in a manner similar to that observed for 
DNA. 
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An in cellulo study has been done on cisplatin-treated E. coli, locating specific 
platinum adducts on helix 24 of the 16S subunit of the ribosome by primer extension of 
extracted RNA.61 Platinum adducts were located in several non-Watson-Crick base 
paired regions that were platinated in the presence of competing GG sequences. Taken 
together the adducts formed in this and the above studies show common features. Binding 
at purine bases, especially guanine, is strongly favored. Just like DNA, 1,2-d(GpG) 
intrastrand cross-link are common, especially in duplexed regions, but are also observed 
in non-duplexed regions. The structural diversity of RNA poses a wider range of possible 
binding sites and platination can occur in non-Watson-Crick paired regions. Local 
structure has tremendous influence on the adduct profile. 
 
Measurements of In Cellulo Pt Binding Targets 
In the context of a cell cisplatin and other Pt(II) drugs have the potential to bind a 
wide range of molecular targets. These targets may include small molecules like 
glutathione, membrane phospholipids, RNA, DNA and proteins.11 An early study by 
Pascoe and Roberts sought to address which classes of biomolecules are targeted by Pt 
complexes in living cells by employing atomic absorption spectroscopy (AAS) to assay 
the amount of cisplatin and its non-pharmacologically active counterpart, transplatin 
(trans-diamminedichloro Pt(II)), bound to the RNA, DNA and protein components of 
HeLa cells. When considered on a Pt(II) per gram of biomolecule basis, the results of this 
study show that significantly more Pt is bound to RNA than to either DNA or protein for 
both Pt complexes. Interestingly, a noticeable difference in cellular uptake between the 
cis- and trans- isomers was also observed. At low micromolar concentrations, where only 
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cisplatin was observed to be cytotoxic, close to twice as much transplatin was found 
bound to RNA, DNA, and protein fractions, although at higher concentrations this 
difference was less pronounced. In addition to differential uptake, the isomeric 
complexes also displayed different extents of DNA interstrand cross-linking; when 
analyzed by density gradient cisplatin was shown to form 10-fold more interstrand cross-
links than transplatin.68  
A similar and more recent study by Miyahara and coworkers also assayed 
cisplatin binding to biomolecules in HeLa cells. By measuring the incorporation of 195mPt 
radiolabeled cisplatin into the protein, RNA, and DNA fractions of HeLa cell components 
researchers determined that the majority of 195mPt was bound to trichloroacetic acid 
insoluble protein components. Both nucleic acids displayed a similar, however lower, 
extent of drug binding.69 When the experiment was repeated using transplatin it was 
again observed that higher amounts of 195mPt(II) were bound to all three classes of 
macromolecules, with the largest increase seen for RNA.70 In addition to these studies, 
significant differences in tissue accumulation,71 cellular accumulation72,73 and DNA 
binding74-78 for different Pt complexes have been observed by AAS and inductively 
coupled plasma mass spectrometry (ICP-MS). The differences observed in these studies 
indicate that, as is observed for cisplatin and transplatin, there could be important and 
pronounced variance in the way different Pt(II) drugs bind to cellular biomolecules, 
however in all cases RNA was a significant target for Pt(II) drugs. 
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Platinum Localization in the Cell 
Characterizing the spatial distribution of Pt(II) binding within a cell provides 
additional information regarding which types of the cellular machines and architectures 
Pt(II) complexes may target. Major cellular targets, with regions important for RNA 
processes, are highlighted in Figure 1.5 and the accompanying studies are portrayed in 
Table 1.1. AAS and ICP-MS have been used as tools to measure Pt drug accumulation in 
several different types of organelles. Cisplatin accumulation in intact mitochondria,79 and 
drug binding to mitochondrial DNA have been quantified using AAS and by 
immunodetection techniques.80,81,82 Similarly, the accumulation of cisplatin and several 
other Pt(II) complexes in the nuclei of drug-treated cells has also been measured.83 More 
recently, Pt accumulation has been detected in vesicles by ICP-MS following the 
treatment of cells with cisplatin, carboplatin and oxaliplatin.84,85 The importance of Pt(II) 
accumulation in these types of cellular compartments is currently unknown. However, 
understanding where in the cell Pt(II) drugs bind may provide further information 
regarding which types of RNA may be targeted by Pt(II) complexes as well as insight 
into biological processing of drug damaged biomolecules.  
Direct imaging techniques have also provided a powerful means to study platinum 
distribution in treated cells. These techniques divide into two main categories: elemental 
imaging, which directly measures the location of the Pt atoms in the cell, and fluorescent 
tagging, which identifies drug binding locations using the fluorescent properties of a 
covalent Pt(II) conjugated fluorophore. 
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Elemental Imaging Techniques 
Elemental imaging techniques are capable of directly detecting the Pt(II) nuclei 
while the drug is in a cell and are therefore broadly applicable in the study of Pt(II) 
localization.86 The majority of these techniques use characteristic X-ray fluorescence 
bands to specifically identify Pt(II) in the presence of other  physiological metals. 
Excitation is typically achieved using either an electron beam, as in electron microprobe 
analysis and X-ray microanalysis, or by using an X-ray beam, as in X-ray fluorescence 
and synchrotron radiation-induced X-ray emission (SRIXE) studies. A similar technique, 
electron microscopy, locates Pt via its electron-dense nature.  
This range of techniques has been applied to a variety of cancerous and non-
cancerous cell lines and tissue samples. The results of these studies are in many cases 
conflicting; however, it is important to note that the significant variations observed are 
most likely due to the different cell lines, drug concentrations, and sample preparation 
techniques used in these studies. In addition, the resolution of elemental imaging is often 
limited, making identification of Pt accumulation in smaller organelles difficult to 
observe. It is important to note that in the following summarized elemental imaging 
studies, the cell lines were continuously treated with Pt(II) complexes for the duration of 
the experiment, and thus incubation time can be used as a basis for comparison.  
Perego and coworkers used electron microscopy to study the early localization of 
cisplatin in an ovarian carcinoma cell line over times ranging from 5-30 minutes. 
Platinum deposits were observed at the plasma membrane, nuclear envelope, and in 
deposits scattered throughout the cytoplasm and nuclear matrices. Interestingly the 
authors also observed Pt deposits spanning through the membranes themselves.87 
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After 4-5 hr of drug treatment Pt is typically observed to accumulate in cell nuclei 
where in addition to DNA replication, transcription and critical RNA-processing events 
also take place. Following 4 hour treatment with cisplatin, Khan and Sadler have 
observed Pt binding in the nucleolus and on the inner edge of nuclear membrane of HeLa 
cells using a combination of electron microscopy and X-ray probe microanalysis.88 
Similarly, after 4 hours of drug treatment Kiyozuka et al. also identified Pt binding to the 
nucleolus and at the periphery of the nucleus in two ovarian carcinoma cell lines. In this 
study the authors noted Pt(II) accumulation in mitochondria89 which is supported by 
similar findings by Meijer et al.90 who observed Pt-DNA binding in mitochondrial DNA 
and in dense heterochromatin and granules surrounding the nucleoli. Interestingly, Pt-
DNA binding was observed to take place in a cell-cycle dependent manner.90 In a 
contrasting study, Ortega et al. reported uniform Pt distribution throughout human 
ovarian cancer cells following treatment for 5 hr with cisplatin.91 At longer timepoints, 
Hambley and coworkers observe that cisplatin, several Pt(IV) prodrugs, and a Br-tagged 
cisplatin analogue accumulate exclusively in the nucleus of ovarian carcinoma cells.92,93  
Platinum accumulation in non-cancerous tissues has been studied in order to 
understand the dose-limiting side-effects of Pt(II) complexes. In these tissues, different 
platinum accumulation patterns have been observed, which may be relevant in assessing 
which RNA-dependent processes are likely affected in different tissues.  In human 
fibroblasts treated with cisplatin for 2 hr, Pt preferentially localized to the nucleolus,94 as 
is observed in many cancerous cell lines. However, rabbit bone marrow treated with 
cisplatin for 10 and 20 hr showed Pt accumulation in the cytoplasm, but not the nucleus.95 
In animal models, Pt distribution has been shown to be tissue specific. In a rat model, Pt 
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accumulation has been observed in the vesicles and microbodies of liver cells and within 
the microbodies, lysosomes, and nuclear matrix of kidney cells.96,97  
 
Fluorescently Labeled Pt Compounds 
Fluorescently tagged platinum compounds have been used for visualizing the 
cellular localization of platinum drugs in real time. These drug conjugates typically 
utilize the chelating ligand ethylenediamine (en) as an anchor for attaching the labels 
such as fluorescein.86 The effects of attaching a large, non-polar fluorophore on the 
biological distribution and processing of platinum drugs must be taken into account in 
interpreting these studies. 
In one of the first studies of this type, Reedjik and coworkers used a 
carboxyfluorescein diacetate-tagged [Pt(en)Cl2] complex and monitored localization of 
the compound within human osteosarcoma cells. In these experiments, cells were treated 
with the complex for 30 minutes, washed, and subsequently imaged. Initially observed 
throughout the cell, the Pt(II) complex accumulated in the nucleus after 1-2 h and after 6-
8 h the compound started to migrate out of the nucleus and into Golgi bodies. These 
organelles seem to be the ultimate destination for this compound at extended time points. 
It is interesting to note that very little difference was observed in how this compound and 
similar fluorescently-labeled dinuclear Pt(II) compounds localized in an ovarian 
carcinoma cell line.98,99 
Howell and coworkers have also used fluorescently-labeled Pt(II) compounds to 
study platination in a human ovarian carcinoma cell line. Following treatment with low 
micromolar concentrations of the complex, the Pt(II)-fluorophore is observed at the 
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periphery of the cellular membrane, in the nucleus, and in small vesicular structures 
scattered throughout the cytoplasm. Supporting biological assays show that while the 
Pt(II)-fluorophore conjugate is ~4-fold less potent that cisplatin, Pt(II)-resistant cell lines 
are similarly insensitive to the two complexes suggesting that the complexes may be 
similarly processed in vivo.100 Further work by Howell and coworkers has used 
fluorescent Pt(II) complexes in concert with specific small molecule inhibitors to show 
that these compounds were first sequestered by lysosomes, subsequently transferred to 
Golgi apparatus and finally into secretory vesicles.101 The accumulation of Pt(II) 
complexes in Golgi bodies has similarily been observed by Gottesman and coworkers 
using a different Pt(II) fluorophore-cisplatin conjugate in the course of studies which also 
identified platination occurring at nucleosomes and within the nucleolus.102 In this case, 
the Pt(II)-fluorophore accumulated more in the cytosol than within the nucleus for a 2 h 
treatment.   
This approach of fluorescently tagging Pt drugs has produced, over several 
studies, a more uniform picture of Pt(II)-conjugate localization than has been observed 
from the direct Pt(II) imaging-based techniques, although the influence of the attached 
fluorophore may affect the outcome of these studies. Nonetheless, these findings 
combined with those of the elemental imaging techniques are beginning to form a picture 
of the cellular components involved in platinum binding and processing, particularly for 
cancerous cells. Initially cisplatin and other Pt(II) drugs enter the cell and accumulate to 
varying degrees in the vesicles and organelles of the cytoplasm, including lysosomes, 
Gogi, and mitochondria. From there Pt enters and accumulates in the nucleus, often 
accumulating along the periphery of the nucleus and in nucleoli. Depending on the 
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treatment conditions and cell type this nuclear accumulation may become greater than 
cytoplasmic accumulation at 1-4 hr. Finally, export from the cell may involve the Golgi 
and vesicles of the secretory export pathway.  
 
 
Figure 1.5. The organelles that accumulate Pt drugs in cancerous cells (indicated with a 
red star) and the locations of important RNA processes within the cell.  References are 
given in Table 1.1. 
 
Table 1.1. Organelles in Which Pt(II) Drug Accumulation Has Been Identified 
Organelle Pt accumulation observed 
by elemental imaging 
Pt accumulation observed 
by fluorescent label 
Nucleus [87-93, 96] [98, 100-102] 
Nucleolus [88-90, 94] [102] 
Mitochondria [89, 90] [101] 
Lysosome  [97] [101] 
Golgi Not observed [98, 101, 102] 
 
Given these sites of Pt accumulation (summarized in Figure 1.5 and Table 1.1), it 
likely that particular RNA targets for Pt(II) drugs are located in the cytoplasm at early 
timepoints and are then located in the nucleus, nucleolus, and mitochondria at later times. 
In these studies the nucleolus, the site of rRNA biogenesis, is a target that has a 
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particularly heavy Pt accumulation. In addition the transcription, splicing, and mRNA 
maturation that occur in the nucleus are also possible targets, as are the transcription and 
translation that occur in mitochondria. Pt complexation may disrupt any or all of these 
important RNA-based processes. In addition, because of their location in the cytoplasm, 
ribosomes, tRNA, and translation may be early targets even though they are not 
associated with sites of specific Pt accumulation.  
 
NAMI-A 
As mentioned above, ruthenium anticancer drugs in general have multiple 
oxidation states and favorable ligand exchange kinetics that take place on order of 
minutes to days, granting high kinetic stability.8 Redox and ligand exchange chemistry 
are considered important to the mechanism of action of NAMI-A. When NAMI-A is 
dissolved in water it undergoes a series of aquation reactions in which the chloride, Im, 
and DMSO ligands all can be lost (Scheme 1.2).103,104 Typically, when in the initial 
Ru(III) oxidation state the Im ligand is retained, while the chloride and DMSO ligands 
are lost.103,104 There is some disagreement in the literature as to whether the chloride or 
DMSO ligand is lost first. Solution conditions such as pH and chloride concentration 
have an effect on the aquation as well. Aquation proceeds more rapidly at pH 7.4 than at 
6.0, with a 20 min half-life for the first aquation reaction at pH 7.4 and a 2 h half-life at 
pH 6.0 (25 °C).104 In addition, at pH 6.0 the DMSO is hydrolyzed first, while at pH 7.4 
both the chloride and DMSO are hydrolyzed in the initial aquation step.104 The presence 
of chloride can slow aquation, but this is a less pronounced effect than observed for 
cisplatin and high chloride concentrations cannot completely repress NAMI-A 
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aquation.104 Once aquated, further complexity is added by the equibria between the aqua 
and hydroxo ligands, producing a wide range of possible active species in solution.  
 
 
Scheme 1.2. The most commonly observed products of NAMI-A aquation. 
 
The reduction potential of NAMI-A is +0.016 V vs. standard calomel electrode 
(SCE) in pH 7.4 phosphate buffer,105 and as such, reduction from Ru(III) to Ru(II) is 
electrochemically attainable by the plasma and cellular reducing agents ascorbate and 
glutathione. The reduced Ru(II) species undergo aquation at a faster rate and demonstrate 
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a greater tendency to lose the chloride and Im ligands, while retaining the DMSO 
ligand.106  
It is not know for certain which Ru species are responsible for the antimetastatic 
activity caused by NAMI-A treatment, but several aquated and reduced species, including 
[Ru(III)Cl4(H2O)(Im)]-, have been shown to be active in cellulo and in vivo.107 In 
addition, the tumor environment itself presents unique features. In tumors the density 
caused by the rapidly dividing cancer cells combined with insufficient blood flow creates 
a hypoxic108,109 and acidic environment110 which may cause drug activation via reduction.  
Many ruthenium drugs also have the ability to mimic iron. NAMI-A is known to 
bind both transferrin (Tf) and human serum albumin (HSA), and it has been suggested 
that this is a mechanism by which it is transported to cancer cells, but there is debate 
about this.111 In one case, both HSA and Tf heavily treated with NAMI-A (4:1 Ru to 
protein ratio) were shown to be ineffective at reducing lung metastasis in mice.112  
NAMI-A exhibits low toxicity, high anti-metastatic activity, and a different 
mechanism of action than that of platinum drugs.8 It causes transient tumor cell cycle 
arrest in the premitotic G2/M phase.113 In addition, multiple other effects have been 
implicated in its antimetastatic activity, including interactions with the extracellular 
matrix, interactions with the cell surface, interference with NO metabolism, and effects 
on tumor metalloproteinases.111,114  
 NAMI-A is known to bind to DNA. NAMI, a highly related drug with a different 
counterion ([Na][trans-RuIIICl4(DMSO)(Im)]), has been shown to cause a marked 
reduction of tumor nucleic acid content.115 In addition, the cytotoxic activity of NAMI-A 
has been correlated with Ru-DNA adduct accumulation. However NAMI-A is much less 
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cytotoxic than cisplatin and, unlike the majority of other ruthenium based anticancer 
drugs, it is believed that NAMI-A’s therapeutic action takes place by a mechanism other 
than DNA binding or direct cytotoxicity. This mechanism of action may involve tumor 
cell cycle arrest and binding to other cellular targets.8,114   
No studies have been done on the effects of NAMI-A treatment on RNA, so it is 
completely unknown how many Ru adducts are accumulating on RNA, what their effect 
might be, or whether they may play a role in its mechanism of action. Some studies have 
been done on the effects of NAMI-A treatment on DNA and the subsequent products 
formed. Just as for cisplatin, the “soft,” nucleophilic N7 site of purine bases, particularly 
guanine, is the main site of coordination for the hydrolysis products of NAMI-A.116,117,104 
Transcriptional mapping combined with denaturing agarose gel electrophoresis has been 
employed to discover that fewer intrastrand GG adducts were produced by NAMI-A 
treatment on double stranded DNA than from cisplatin treatment.118 The other main 
adduct formed by NAMI-A in this study is most likely a monofunctional adduct. In 
addition, this study demonstrated that fewer interstrand cross-links were formed in 
dsDNA from NAMI-A treatment than from cisplatin treatment. In vitro studies have used 
calf thymus or plasmid DNA to compare the effects of NAMI-A and cisplatin treatment 
on global measures of DNA structure such as thermal denaturation or circular dichroism 
spectroscopic signatures. The results demonstrate less overall structural effects following 
NAMI-A treatment, which could be due to a greater number of Ru monoadducts 
formed.119,120 The structural causes of this altered adduct profile are unknown. Taken 
together, these results suggest that for RNA a preference for purine bases can be 
expected, and that a different adduct pattern than that observed for cisplatin treatment 
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should be expected. Based on the DNA results, there could be a higher proportion of 
monofunctional adducts (which are expected to have less impact on RNA structure and 
function). However it is also possible that the wider variety of structures available in 
RNAs may offer binding geometries more suitable for the forming cross-links than those 
offered in canonical B-form DNA.  
 
Bridge to Chapter II 
 In this dissertation the effects of anticancer metallodrugs on RNA were 
investigated with two drugs: cisplatin and NAMI-A. Cisplatin was chosen because it is 
the most studied anti-cancer therapeutic and it is known to bind to RNA. In addition 
cisplatin has been shown to be able to induce nuclear-independent apoptosis in 
endonucleated mouse proximal tubule cells, suggesting the presence of alternative targets 
from nuclear DNA.121 NAMI-A is a particularly promising Ru anticancer drug which is 
in Phase Two of clinical trials. It was chosen because is known to bind to DNA (RNA 
binding has not been studied), but it has a different mechanism of action and different 
nucleic acid binding properties than cisplatin. Both in vitro and in cellulo studies were 
done to characterize the interaction of these drugs with RNA. 
The following chapter focuses on cisplatin, describing in vitro kinetic and 
mapping studies of cisplatin induced cross-linking across an internal loop in a model of 
the active core of the spliceosome that were aimed at characterizing a novel RNA-
platinum binding mode.  
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CHAPTER II 
RAPID CROSS-LINKING OF AN RNA INTERNAL LOOP BY THE 
ANTICANCER DRUG CISPLATIN 
 
This chapter covers kinetic studies comparing the platination rate of RNA and 
DNA oligonucleotides, mapping experiments that localized the platinum binding sites, 
and MALDI-MS data that demonstrate the stoichiometry of the platinated products. It 
includes important contributions from Dr. Erich G. Chapman and Prof. Victoria J. 
DeRose. I performed the kinetic studies, prepared the samples for the MALDI-MS 
experiments, and co-wrote the manuscript. Dr. Erich G. Chapman ran the MALDI-MS 
samples, performed the mapping experiments, and co-wrote the manuscript. Prof. 
Victoria J. DeRose guided this project and provided significant editorial feedback. This 
project was started by Prof. Victoria J. DeRose at Texas A&M University and the first 
studies were carried out by Dr. Janell E. Schaak. The main construct in this study, a 
model of a subdomain of the active core of the spliceosome, was designed and 
characterized by Sarah Tate and Dr. Janell E. Schaak. Reproduced with permission from 
Hostetter, A. A.; Chapman, E. C.; DeRose, V. J. J. Am. Chem. Soc. 2009, 131, 9250-
9257. Copyright 2009 American Chemical Society.    
 
Introduction 
Cisplatin (cis-diamminedichloroplatinum(II)) is the flagship compound for a 
series of platinum(II) anti-tumor agents employed in the treatment of a wide range of 
cancers.1-3 Cisplatin activity involves intracellular exchange of the labile chloride ligands 
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and ultimate coordination to “soft” biomolecular donor sites. In vivo, cisplatin is known 
to bind to multiple targets including DNA, RNA, proteins, and small-molecule ligands. 
Drug binding to adjacent purines on genomic DNA has been linked to the induction of 
apoptosis, a foundation of antitumor activity. Despite their prevalent use, a 
comprehensive understanding of additional drug-related biological processes is still 
forming for the platinum antitumor compounds.  
Early studies that are often cited in identifying DNA as a target for cisplatin 
reveal that, on a per nucleotide basis, drug binding to DNA and RNA is roughly 
equivalent.4,5 Additional studies have shown that platinum treatment is capable of 
interfering with transcription,6-8 and that critical RNA-dependent activities such as 
splicing9 and translation5,10,11 are inhibited when measured in cell extracts. Combined, 
these studies suggest that cisplatin binding to RNA may contribute to the drug’s in vivo 
effects. A limited number of studies have presented further details concerning 
interactions of cisplatin with RNA. Elmroth, Chow, and coworkers have previously 
communicated enhanced reactivity and more pronounced dependence of reaction rate on 
ionic conditions for the reaction of a 13nt RNA hairpin in comparison with a DNA 
analogue.12 Elmroth and coworkers have additionally suggested binding locations for 
cisplatin near the G•U wobble pair in a tRNAAla acceptor stem,13,14 and have explored 
platinum-RNA adducts for directing RNA silencing.15 Cisplatin has been shown by 
Danenberg and coworkers to inhibit in vitro activity of a Group I intron ribozyme.16 Very 
recently, Rijal and Chow have reported cisplatin as a structural probe to identify 
accessible purine bases in bacterial ribosomes.17 These studies suggest intriguingly 
selective cisplatin-RNA reactivity, and call for more detailed kinetic analyses and 
 31 
 
comprehensive characterization of the nature of the platinated products in complex 
RNAs.   
A common characteristic of naturally occurring metal sites in RNA is the 
involvement of ligands that are distant in primary sequence but brought into proximity in 
the folded RNA structure.18-20 By cross-linking two such ligands, cisplatin-induced 
chelation, whether in naturally occurring metal sites or novel target sites, has the potential 
to inhibit activities that depend on the dynamic nature of RNA. The spliceosome is an 
example of an RNA machine that is dependent on dynamic rearrangements for 
function.21,22 One key step in spliceosomal function is the formation of a complex 
between the U2 and U6 snRNAs that is implicated in the first step of the pre-mRNA 
splicing.23 Here we provide an in vitro analysis of the reaction between aquated cisplatin 
and a 41nt RNA construct termed BBD (branch-bulge domain) that contains the purine-
rich internal loop from U2 and U6 RNA strands (Figure 2.1).24 We show that platinum 
forms a novel intrastrand cross-link across the internal loop of BBD and an interstrand 
cross-link in a two-piece construct. Additionally, we report that, under biologically 
pertinent ionic conditions, platination of both BBD and a related 40 nt RNA hairpin is 
~5-fold faster than for a DNA hairpin analog. MALDI-MS data are presented that 
complement the conclusions from our biochemical studies. Taken together, these results 
indicate facile cisplatin-induced adduct formation across an RNA internal loop and fast 
platination kinetics of RNA oligonucleotides. 
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(a)
(b)
 
Figure 2.1. (a) The proposed secondary structure of a human U2:U6 snRNA core 
complex including bound branch oligonucleotide.18 Conserved nucleotides are in pink. 
(b) Predicted secondary structure of the BBD RNA subdomain used in this study, with 
invariant nucleotides again highlighted in pink. 
 
Evidence of Cisplatin-RNA Cross-Linking 
RNA and DNA oligonucleotides used in this study are shown in Figure 2.2a. The 
BBD RNA subdomain contains a purine-rich internal loop flanked by helical regions, 
whereas the RNA and DNA hairpin sequences (RNA HP and DNA HP) are fully base-
paired. In previous studies, reaction of RNA or DNA with cisplatin has resulted in 
product species that are typically observed to migrate more slowly when analyzed by 
denaturing polyacrylamide gel electrophoresis (dPAGE).25,26 Slower migration of 
platinated oligonucleotides is likely due to added molecular weight and a decrease in the  
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Figure 2.2. (a) Oligonucleotide sequences and predicted secondary structures. The BBD 
internal loop is highlighted in red. Differences in sequence relative to BBD are shown in 
blue. (b) Formation of a higher-mobility BBD product upon platination of BBD. (c) 
Confirmation of cisplatin-induced cross-linking in BBD internal loop sequence, showing 
products of platinum treatment with (i) BBD, (ii) SBBD hybrid, and (iii) individual 
strands of SBBD. Conditions: (b) 0.2 M 5’ 32P-labeled BBD treated with indicated 
concentrations of cisplatin for 1.5 h in deionized water, analyzed by 18% dPAGE, and 
visualized by autoradiograph; (c) 20 M (0.2 nmol) RNA reacted with 10x cisplatin (200 
in 5 mM TEA (pH 7.8), 12-15 hr, 37 °C, analyzed by 20% dPAGE, and visualized 
by staining with methylene blue. 
 
overall charge of the nucleic acid through binding of a [Pt(NH3)2]2+ fragment. By 
contrast, the reaction of cisplatin with BBD results in a product species with higher 
mobility (Figure 2.2b). Faster mobility under denaturing conditions may be caused by 
intrastrand cross-linking,27,28 which was hypothesized to occur across the purine-rich 
internal loop region of the BBD RNA. In order to test this hypothesis, the BBD internal 
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loop sequence was embedded between two new duplex sequences, creating a two-piece 
“split” BBD duplex (SBBD, Figure 2.2a). Platination of SBBD results in cross-linking of 
the two strands, as observed unambiguously by dPAGE (Figure 2.2c). Platination of the 
individual upper or lower SBBD strands does not result in a cross-linked species, 
although the presence of secondary platination sites is indicated by the dispersion of the 
dPAGE product bands (Figure 2.2c). These data indicate that cisplatin creates a cross-link 
across the internal loop of BBD RNA.  
 
Identification of Cross-Linked Nucleobases  
In order to identify the specific bases involved in formation of an intrastrand 
cross-link, the proposed cross-linked product (BBD-XL) was isolated following dPAGE 
and mapped by partial alkali hydrolysis. Using 5’ end-labeled RNA, normal hydrolysis 
products are expected to be observable up to the 5’ side of the cross-linked site.28-30 
Hydrolysis products that contain the cross-linked site will result in significantly higher 
molecular weight species and unusual gel mobilities, leaving a gap in the hydrolysis 
ladder following the 5’ cross-linked site. 28-30 As displayed in Figure 2.3, clear BBD-XL 
hydrolysis products are observed for nucleotides 3’ to A8 but not at G9, identifying G9 as 
the major 5’ site involved in the internal cross-link. An additional faint band at U10 
suggests G11 as a minor secondary site for platinum-induced cross-linking. In the cross-
linked species generated using the two-piece SBBD complex, the site equivalent to G9 
was again identified as one major adduct site (Figure A.1, Appendix A). Using this 
SBBD construct, hydrolysis mapping also identified the site corresponding to G31 as the 
cross-linking partner on the other side of the internal loop (Figure A.2, Appendix A). 
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Figure 2.3. (a) Secondary structure of BBD representing the location of the cisplatin-
induced cross-link found in BBD-XL. (b) Cleavage products produced by the alkali 
hydrolysis of isolated BBD-XL. Lanes from left to right. Control lanes (untreated BBD 
RNA)- C: control 5’-end-labeled untreated BBD. T1: G-specific sequence ladder 
generated by partial nuclease digestion by RNase T1. U2: A-specific sequence ladder 
generated by partial nuclease digestion by U2 RNAse. OH-: Reference alkali hydrolysis 
ladder. BBD-XL lanes- C: dPAGE-isolated BBD-XL. OH- Lanes: dPAGE-isolated 
BBD-XL treated under alkali hydrolysis conditions for increasing amounts of time (see 
Methods). Arrows indicate major (thick arrow, G9) and minor (thin arrow, G11) sites of 
platinum coordination.  
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The identification from dPAGE-isolated products of the intrastrand cross-link in 
BBD and the analogous interstrand cross-link in the SBBD hybrid strongly suggests that 
internal loop cross-linking is a major structural determinant for altered gel mobility upon 
platinum coordination to BBD. 
 
Cisplatin-RNA Reaction Rates  
The in vivo relevance of cisplatin-RNA reactions, including the internal loop 
cross-linking reaction observed here, depends in part on their rates relative to adduct 
formation with DNA or other cellular targets. In evaluating the reaction rates of cisplatin 
with the oligonucleotides of Figure 2.2a, kinetic studies were performed at 37 °C and in a 
background of 0.1 M NaNO3/1 mM Mg(NO3)2 in order to approximate cation 
competition in vivo. Nitrate salts were used instead of chloride salts to prevent bias of the 
observed reaction rates due to an increase in the cisplatin anation rate.31 Because the 
aquation of cisplatin has been shown to be the rate-limiting step for reactions with 
oligonucleotides under similar conditions, cisplatin was aquated by reaction with AgNO3 
immediately before use.32 RNA concentrations of 0.1 M and platinum concentrations of 
at least 125-fold excess were used to ensure pseudo-first order conditions for the reaction 
(Figure A.4, Appendix A). Reaction products were analyzed following separation by 
dPAGE and autoradiography. Under these conditions, all data fit well to a single 
exponential function, indicating that a single rate-limiting step dominates the kinetics of 
product appearance in each case.   
In addition to monitoring internal cross-link formation in BBD, reactions of 
aquated cisplatin with two related hairpin structures were monitored. RNA HP and DNA 
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HP (Figure 2.2a) retain the flanking helical and terminal loop sequences of BBD but 
replace the internal loop region with a fully base-paired sequence. These hairpin 
constructs provide control sequences having similar base composition, length, and 
terminal loops to those of BBD. Reaction of aquated cisplatin with both HP constructs 
results in products that migrate more slowly, in contrast to the faster-migrating cross-
linked species produced with BBD (Figure 2.4a). As observed from Figures 2.4a and 
2.4b, both RNA sequences (BBD and RNA HP) react at similar rates of kobs =  9.8(1.0) × 
10-5 and 8.3(2) × 10-5 s-1 respectively in 50 M CP, pH 7.8 (Table A.1). Product 
formation for the DNA construct is 5-6 fold slower, with an observed rate constant of 
1.7(2) × 10-5 s-1 under identical conditions. The calculated second-order rate constants are 
krxn2 = 2.0(2), 1.7(3), and 0.33(3) M-1 s-1 for BBD, RNA HP, and DNA HP respectively.   
Reaction rates were also investigated, under identical buffer conditions, for the 
two-stranded SBBD hybrid substrate for which product formation results in a clearly-
separated cross-linked species (Figure A.1c and A.3, Appendix A). For the SBBD, a 
pseudo-first-order rate constant of kobs= 5.2(3) × 10-5 s-1 and a calculated second-order 
rate constant of krxn2= 1.1(1) M-1 s-1 were obtained in 50 M aquated cisplatin (Figure A.3 
and Table A.1, Appendix A). These values are approximately 50% of those determined 
for BBD, but still reflect faster reaction rates than observed for the DNA HP.  A likely 
explanation for the slower reaction rate observed for intermolecular cross-linking of the 
SBBD construct in comparison with intramolecular cross-linking in BBD is the 
incomplete hybridization of the SBBD strands under these reaction conditions (see 
Materials and Methods). Nonetheless, the fact that similar values are observed for cross-
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linking in both BBD and the two-piece SBBD suggests that similar rate-limiting steps 
guide the internal loop cross-linking reaction regardless of RNA construct.   
 
 
Figure 2.4. (a) Time-dependent product band appearance following treatment of 
radiolabeled RNA and DNA substrates with aquated cisplatin and analysis by dPAGE. 
Product bands are labeled BBD-XL, rHP-P1, and dHP-P1 for BBD, RNA HP (rHP), and 
DNA HP (dHP) respectively. (b) Comparison of the reaction rates of aquated cisplatin 
with BBD (open circles), RNA HP (filled circles), and DNA HP (triangles). Data are fit 
to a pseudo first-order rate expression as described in Materials and Methods. Conditions 
in (a): 0.1  oligonucleotide, 50 µM aquated cisplatin, 100 mM NaNO3, 1 mM 
Mg(NO3)2, and 5 mM TEA (pH 7.8) at 37 °C. 
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The reactions of aquated cisplatin with BBD and SBBD are pH-dependent, 
increasing in rate as the pH is lowered. At pH 6.8, second-order rate constants of 8.5(7) 
and 6.8(2) M-1 s-1 are measured for BBD and SBBD, respectively (Table A.1, Appendix 
A, data not shown). Based on known protonation equilibria for aquated cisplatin species, 
this rate enhancement likely reflects protonation of a cisplatin hydroxide ligand to aqua 
ligand on platinum(II), and is a closer approximation to rates that might be expected for 
in vivo conditions.  
 
Analysis of Platinated RNAs by MALDI-MS 
As described above, platination of the RNA and DNA domains used in this study 
results in products that have distinctly altered mobilities when analyzed by dPAGE. To 
further analyze these products, MALDI-MS was used to identify platinum-
oligonucleotide species33 in samples isolated from the dPAGE gels. MALDI-MS data for 
the RNA and DNA HP sequences reacted for 5 h at a ratio of 5:1 
platinum/oligonucleotide are shown in Figure 2.5a. Products containing [Pt(NH3)2]2+ 
adducts appear at the oligonucleotide mass plus increments of 229 amu. Additional 
lower-intensity peaks are often present at ~+17, +23 and +39 amu that are ascribed to 
residual H2O/OH/NH4+, Na+, and K+, respectively. These features appear in untreated 
RNA as well as platinated RNA, and their presence along with the breadth of the features 
precludes identification of [Pt(NH3)2X] (X = H2O, OH- , or Cl- ) species. Although 
MALDI-MS is not precisely quantitative, comparison of relative intensities within  
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Figure 2.5. (a) Positive-ion mode MALDI mass spectra of products following aquated 
cisplatin treatment of the RNA HP and DNA HP and isolation via dPAGE. Product bands 
are labeled rHP-P1 and dHP-P1 for RNA HP (rHP), and DNA HP (dHP), respectively. 
(b) Positive-ion mode MALDI mass spectra of the products of 23 h reactions of RNA HP 
and DNA HP with cisplatin under the reaction conditions used for Figure 2.4. (c) 
Sequence and predicted secondary structure of LSBBD. The BBD internal loop is 
highlighted in red. Differences in sequence relative to BBD are shown in blue. Image and 
subsequent MALDI-MS of the two main electrophoretic bands resulting from cisplatin 
treatment of LSBBD (LS), with (LS) product band is labeled LS-XL. Conditions: (a) 
Reactions were performed with 30 µM oligonucleotide, 150 µM aquated cisplatin, 100 
mM NaNO3, 1 mM Mg(NO3)2, and 5 mM MOPS (pH 6.8) at 37 °C for 5 h. The bands 
were separated by 20% dPAGE, stained with methylene blue, and then excised. The 
MALDI was performed in 3-hydroxypicolinic acid. (c) Same as in (a), except that the 
reaction contained 90 µM cisplatin. 
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identically treated samples provides qualitative information on relative populations of the 
major RNA-platinum adducts.   
The data in Figure 2.5 show that RNA and DNA HP samples, treated under the 
reaction conditions described above, separate into upper and lower dPAGE bands that 
both contain platinated oligomers. As expected from their slower electrophoretic 
mobility, samples isolated from the upper band of these gels show a higher extent of 
platination. At a ratio of 5:1 Pt/oligomer, species with bound 1-3 [Pt(NH3)2]2+ are present 
in the lowest-running dPAGE bands, whereas the higher bands contain oligomers with 2-
4 bound [Pt(NH3)2]2+ ions (Figure 2.5a). Consistent with the observation that RNA 
exhibits a faster reaction time, a higher population of the +4  [Pt(NH3)2]2+ species is 
observed for the RNA HP sample than is found for the DNA analogue at the same time 
point. Faster reaction kinetics with RNA are also evident from bulk analysis of samples 
that are reacted for 23 hr in the high platinum/oligonucleotide ratios used for kinetic 
studies. In this case, the bulk DNA HP sample shows an overall adduct distribution that 
has major populations of 2-3 bound [Pt(NH3)2]2+, distinctly fewer than the 5-6 
[Pt(NH3)2]2+ in the highest amplitude MALDI-MS peaks for the RNA HP sample treated 
under identical conditions (Figure 2.5b).  
From these data, it is apparent that the products separated by dPAGE all contain 
multiple platinum adducts. In the case of the mainly helical hairpin samples, the major 
products quantified for kinetics analysis are separated as a lower-mobility species that 
contain on average one more [Pt(NH3)2]2+ ion (Figure 2.5c). Although not a complete 
study, these data are broadly consistent with a model in which one site on the HP 
sequence reacts more quickly with cisplatin, and also causes a conformational change 
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resulting in a distinct lower-mobility species. Slower platination reactions occur at other 
sites, creating products that are not clearly separated by these dPAGE conditions.    
The products of BBD platination were also analyzed by MALDI-MS. If a similar 
model holds in which one faster-reacting site results in altered gel mobility, then for the 
BBD reactions, it is predicted that the higher-mobility, cross-linked products will also 
contain on average one additional [Pt(NH3)2]2+ ion. An alternative model for reactions of 
platinum with the BBD sequence is that the cross-linking and non-cross-linking sites 
react at equal rates, which would result in an equal distribution of platinum in both 
dPAGE bands. To simplify the MALDI-MS data, a modified BBD sequence that 
maintains the internal loop but reduces the number of other purine sites was employed 
(Figure 2.5b). MALDI-MS spectra of platinated LSBBD shows that peaks from the 
faster-migrating product band are indeed shifted by approximately + 1 [Pt(NH3)2]2+ 
fragment (Figure 2.5c). Additional evidence that the gel bands observed for platinated 
BBD differ by one [Pt(NH3)2]2+ fragment is provided by the dependence of reaction rates 
on platinum concentration. With platinum in large excess, the observed reaction rates 
vary linearly with a slope of 1.1 (r2 = 1.0, Figure A.4, Appendix A), consistent with a 1:1 
ratio between platinum and product. 
  
Discussion 
Understanding of the biological roles of RNA has vastly expanded over the last 
three decades.34 RNA-based regulation is now known to occur through gene silencing 
and RNAi pathways,35,36 as well as through specific binding of small molecules in the 
structured regions of riboswitches.37-40 Complex RNA structures support catalytic active 
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sites,41 and dynamic RNA-protein rearrangements take place throughout regulatory 
pathways42-44 and in complex cellular machineries such as the spliceosome.22 These 
factors serve as the basis for the recent push in advancing RNA as a drug target and spur 
interest in understanding how existing nucleic acid-targeted drugs might act in previously 
unidentified pathways.45,46 Cisplatin provides an example of a known DNA-binding 
compound that might have unique interactions with complex RNA structures. Factors that 
may be relevant to structurally diverse RNAs have been encountered in studies of 
platinated DNA hairpins, platinum-cross-linked quadruplex structures, and platinated 
DNA-protein complexes.47-53 Additionally, preliminary investigations have already begun 
to address cisplatin’s use as a structural probe and as drug conjugate for targeting 
RNA.15,17,54,55   
This report describes cisplatin cross-linking across the internal loop of a 41nt 
RNA branch-bulge subdomain (BBD) that is derived from the U2:U6 snRNA complex 
proposed to form the active core of spliceosome (Figure 2.1).23,24 Cisplatin-induced 
intramolecular cross-linking takes place between G bases located in opposing sides of the 
BBD internal loop. In a cellular context, cross-linking of this type could have the 
potential to disrupt binding of the branch oligonucleotide or dissociation of the U2:U6 
complex. It is interesting to note that the 3’ side of the BBD internal loop corresponds to 
an invariant region of the U6 snRNA that is hypothesized to contain essential metal 
binding sites in the biological complex.56,57 The ability of cisplatin to compete for pre-
organized metal bind sites in RNA is unestablished and presents an interesting possibility 
for predicting in vivo drug binding locations.  Further studies will also focus on the 
sequence requirements and generality of cisplatin-based drug interactions with structured 
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RNAs. Initial experiments indicate that this cross-linking reaction is tolerant of single 
base substitutions in the BBD internal loop, but that substitution of G31, the 3’ partner in 
majority cross-link, with non metal-coordinating U results in a slightly different product 
as reflected by altered mapping data (data not shown). These limited studies indicate that 
platinum-induced cross-link formation is not strictly limited to internal loops with this 
exact BBD sequence and is likely to take place in other structured RNAs. In general, 
cisplatin cross-links in functional RNAs could disrupt a host of cellular processes that 
rely on RNA’s dynamic structure.  
Drug-binding kinetics may be an important factor governing the significance of 
cisplatin-RNA adducts in vivo. In order to begin to address this topic, here we compared 
the in vitro reaction rates of similar RNA and DNA oligomers with cisplatin. Somewhat 
surprisingly, the RNA constructs exhibit reaction rates that are 5-6 times faster than those 
measured for the DNA construct. In a related study, Elmroth and coworkers observed 
faster binding by other platinum(II) compounds to a 13nt RNA hairpin in comparison 
with its DNA analogue. Although that study used different reaction conditions than 
employed here, most notably lower ionic strength, the reported rate constants are within 
an order of magnitude of those in Table A.1.12 Combined, these observations support 
RNA as a kinetically competitive target for cisplatin. 
The application of polyelectrolyte theory to the platination of RNA or DNA 
suggests a model involving entry of a charged platinum species into the condensed cation 
atmosphere of a nucleic acid, followed by irreversible monoadduct and diadduct 
formation. 12,58-60 The range of literature values for the rate of monoadduct formation on 
duplex DNA by [Pt(NH3)2Cl(OH2)]+ vary from ~0.1-1 M-1 s-1.61-63 From this study, the 
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calculated second order rate constant for the platination of the DNA HP is 0.33(3) M-1 s-1 
and lies within this range, while the rates observed for the RNA constructs are somewhat 
faster at ~2 M-1 s-1 (Table A.1). The observation that similar rates are obtained for 
monoadduct formation on two structurally distinct RNAs indicates that broader factors 
such as electrostatic potential and oligomer flexibility likely dictate enhanced reactivity 
when compared with DNA. Individual contributions of these factors are currently under 
investigation. 
MALDI-MS allows identification of nucleic acids with bound [Pt(NH3)2]2+ 
fragments33 and was used to analyze bulk reaction mixtures and dPAGE isolated 
oligomers in this study. MALDI-MS analysis of platinated oligomers isolated from 
dPAGE shows an average of one additional [Pt(NH3)2]2+ fragment in the product bands. 
This observation supports a model in which specific sites within each oligomer react 
quickly with cisplatin and are responsible for the structural distortions leading to altered 
gel mobility. Previous observations of kinetically preferred sites for platinum adduct 
formation on DNA have been reported. Enhanced reactivity can be based on 
electronegativity and target site geometry, as influenced by the nucleotide identity as well 
as oligonucleotide length, and secondary and tertiary structure.49,53,64-71 Particularly 
relevant to this study is the observation of cross-strand adduct formation by 
[Pt(NH3)2(OH2)2]2+ in telomeric DNA model sequences.48,53 An even greater variety of 
platinum adducts might be expected for RNA based on its structural diversity and ability 
to specifically chelate divalent metals.18-20   
The biological lifetime of each nucleic acid is an important factor in translating 
the faster in vitro rates observed for RNA in this study into a cellular context. In normal 
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human cells the most rapidly turned-over class of RNA is mRNA. Median mRNA 
lifetimes in human cell lines have been reported to be ~10 h, with a wide range of decay 
rates that vary by ~500-fold.72 Both tRNA and rRNAs have significantly slower turnover 
rates, and lifetimes predicted to be on the order of days for average adults.* The lifetimes 
and abundance of cellular RNAs tsuggest that platinum drug binding could occur on a 
timescale allowing it to affect RNA processes within treated cells. The types of cellular 
RNAs that are sufficiently accessible for platinum adduct formation, and the range of 
cellular consequences that could result from cisplatin interactions with RNA including 
interstrand cross-linking such as is observed in this study, are topics that remain to be 
addressed. 
 
Materials and Methods 
Nucleic Acid Substrates 
All RNAs, except BBD, were purchased from Dharmacon, Inc. DNA was 
purchased from Integrated DNA Technologies. BBD was transcribed in vitro from a 
plasmid template using T7 RNA polymerase. All nucleic acid substrates were purified by 
20% dPAGE, eluted, then desalted and concentrated using Millipore YM-3 Centricon 
tubes. Subsequent buffer exchange and desalting was often accomplished using GE 
Healthcare G-25 Microspin Columns.  
 
 
                                               
* Measured turnover rates range from 0.034-0.0048 µmol/kg-day for rRNA and 0.46-0.88 
µmol/kg-day for tRNA.73-76 Based on the calculation put forth by Petersen and 
coworkers,74 this roughly corresponds to 12-29 days for rRNA and 17-29 for tRNA in 
average adults. 
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5’ End-Labeling 
Prior to radiolabeling, the 5’ end of BBD was dephosphorylated using Antarctic 
phosphatase (New England Biolabs). 5’-OH Oligonucleotides were end-labeled with T4 
polynucleotide kinase (USB) using γ32P-ATP (Perkin Elmer). End-labeled 
oligonucleotides were purified by 20% dPAGE followed by overnight elution from 
excised gel bands. The resulting eluent was ethanol precipitated and desalted or buffer-
exchanged as described above. 
 
Cisplatin Aquation 
Cisplatin (Sigma-Aldrich) was stored as a 1 mM solution in 10 mM NaCl in the 
dark at 4 °C. Immediately before use, cisplatin was aquated with 0.95 equivalents of 12 
mM AgNO3 (stored in the dark). The aquation reaction was incubated at 50 °C for 1 h, at 
which time AgCl was precipitated by centrifugation. The supernatant solution was 
removed and diluted accordingly. Based on 195Pt NMR (data not shown), the main 
platinum species varied by pH: [Pt(NH3)2Cl(OH2)]+ for pH 6.8 and [Pt(NH3)2ClOH] for 
pH 7.8. 
 
Platination of BBD (Figure 2.2b)  
A trace amount of 5’-end labeled BBD with 0.2 M unlabeled BBD was annealed 
by heating to 90 C for 90 s followed by cooling to room temperature, then reacted with 
0-40 M cisplatin in deionized water for 1.5 h at 37 C. The bulk reaction mixtures were 
mixed with formamide loading buffer and immediately applied to 18% dPAGE. Results 
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were imaged using a Molecular Dynamics phosphor screen and scanned on a Molecular 
Dynamics Storm 860.  
 
Comparative Platination of SBBD and BBD (Figure 2.2c) 
Twenty micromolar (0.2 nmol) of BBD RNA, each individual SBBD strand, or 
the SBBD hybrid was annealed and rested on ice for 30 min. RNAs were then incubated 
in the presence or absence of 200 µM cisplatin (added as a 1 mM solution with 8 mM 
NaCl) in 5 mm triethanolamine (TEA) for 12-16 hr at 37 °C. Reaction mixtures were 
analyzed on 20% dPAGE and visualized by staining with methylene blue. 
 
Isolation of 5’ End-Labeled, Cross-Linked RNAs 
BBD: 5’End-labeled BBD in the presence of 0.1 M unlabeled BBD was 
annealed and reacted with aquated cisplatin in 100 mM NaNO3, 1mM Mg(NO3)2, and 5 
mM 3-(N-morpholino)propanesulphonic acid (MOPS) (pH 6.8) at 37 C for 23 h. 
Reaction products were isolated via excision from 18% dPAGE. RNA was eluted 
overnight into deionized water and desalted using in-house prepared G-25 sephadex spin 
columns (BioRad).  SBBD: One 5’end-labeled strand was annealed in 10 M of the 
unlabeled complement RNA in 12.5 mM NH4NO3 and reacted with 100 M aquated 
cisplatin for 23 h. The cross-linked product was excised from 20% PAGE and eluted 
overnight into deionized water. Following speedvac concentration, SBBD cross-links 
were desalted using G-25 sephadex spin columns (GE Healthcare). 
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Hydrolysis Mapping of Cross-Linked RNAs  
Trace 5’ end-labeled, cross-linked RNAs were dried to completion in the presence 
of 0.2 pmol unlabeled RNA corresponding to the 5’end-labeled strand. Samples were 
then resuspended in 50 mM Na2CO3/NaHCO3 (pH 9.5), 1 mM EDTA and reacted at 90 
C for times ranging from 5 to 25 min. The reaction was quenched by the addition of 8 M 
urea, 10 mM sodium citrate (pH 3.5), 0.005% (w/v) xylene cyanol loading buffer and 
held on dry ice until electrophoresis. The results were analyzed on 15 or 20% dPAGE 
(BBD and SBBD respectively) then visualized via phosphorimaging.   
Reference lanes of 5’ end-labeled un-cross-linked RNAs were generated from 
hydrolysis as above and by partial nuclease digestion by RNase T1 (Ambion) or U2 
(Pierce/Thermo Scientific). Briefly, 5’-end-labeled RNA with 0.2 M of the 
corresponding unlabeled RNA in 8 M urea, 10mM sodium citrate (pH 3.5), 0.005% (w/v) 
xylene cyanol was reacted for at 50 C for 12-15 min with 1U T1 RNase, or 0.2U U2 
RNase. Samples were then held on dry ice until electrophoresis.   
 
Kinetic Analysis 
Prior to kinetic analysis, 0.1 µM oligonucleotide with trace 5’end-labeled material 
was annealed in buffered solution by heating to 90 C for 90 s followed by gradual 
cooling to room temperature or, for the case of the SBBD hybrid, resting on ice for 30 
min. Buffers included either 100 mM NaNO3, 1 mM Mg(NO3)2, 5 mM triethanolamine 
(TEA) (pH 7.8) or 100 mM NaNO3, 1 mM Mg(NO3)2, 5 mM MOPS (pH 6.8) depending 
on desired pH. Freshly aquated cisplatin was added to final concentrations of 13, 25, or 
50 µM, and the reactions incubated at 37 °C for times ranging from 1 min to 35 h. 
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Aliquots were removed and stopped by ethanol precipitation or dilution with formamide 
and freezing. These aliquots were applied to 18-19% dPAGE and visualized by 
autoradiography. Each kinetic experiment was repeated at least three times. Molecular 
dynamics ImageQuant software version 5.0 was used to quantify the reaction products 
from each kinetics experiment. Rate constants were generated from data analysis using 
SigmaPlot version 8.0. 
 
MALDI-MS 
Isolation of platinated oligonucleotides for MALDI-MS analysis: 30 µM of an 
oligonucleotide was annealed in 100 mM NaNO3, 1 mM Mg(NO3)2, 5 mM MOPS (pH 
6.8) and reacted with either 90 µM aquated cisplatin for LSBBD or 150 µM for RNA HP 
and DNA HP. Samples were incubated at 37 C for 5 h, at which time they were applied 
to 19% dPAGE. Products were stained with methylene blue and excised. 
Oligonucleotides were recovered via electroelution using a Schleicher and Schuell 
Elutrap electro-seperation system, concentrated, and desalted. Bulk time-course reactions 
for MALDI-MS analysis: 0.6 nmol of an oligonucleotide was reacted under identical 
conditions to those used in kinetics experiments (see above). Reactions were incubated 
for 1 or 23 h and stopped by ethanol precipitation, dryed, and desalted using G-25 
sephadex spin columns. 
Oligonucleotide samples (~50-100 pmol) were additionally desalted on C18 
ZipTips (Millipore) following the manufacturer’s protocol for RNA. RNA was eluted in a 
matrix solution containing 41 mg/mL 3-hydroxypiccolinic acid and 4.5 mg/mL 
diammonium citrate then applied to the sample plate. MALDI-MS analysis was 
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performed on a Waters QTof Premier mass spectrometer in positive ion mode using V-
mode optics. 
 
SBBD Thermal Denaturation 
Thermal denaturation of SBBD, in a ‘kinetics’ buffer of 100 mM NaNO3, 1 mM 
Mg(NO3)2, 5 mM TEA (pH 7.8), was monitored on a Varian Cary 300 Bio UV-visible 
spectrophotometer with multicell holder and temperature controller. These data were fit 
with the accompanying software, giving a Tm of 59 °C and a calculated Kd at 37 °C of 6.8 
× 10-9. Based on this Kd, approximately 60% of the SBBD hybrid would be formed 
during the kinetic analyses, which used a concentration of 0.1 M for each SBBD strand.   
 
Bridge to Chapter III 
This chapter has described in vitro experiments characterizing a novel platinum-
RNA cross-link in a subdomain of the active core of the spliceosome. The results of this 
study motivated us to explore cisplatin-induced RNA platination in the context of a cell. 
Chapter III describes in cellulo studies in S. cerevisiae in which Pt accumulation in yeast 
RNA species was quantified by ICP-MS, and the effects of cisplatin treatment on S. 
cerevisiae were examined using clonogenic and morphologic assays. 
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CHAPTER III 
CHARACTERIZATION OF RNA-PT ADDUCTS IN S. CEREVISIAE 
 
This chapter describes in cellulo studies of cisplatin treated S. cerevisiae in which 
Pt accumulation in yeast RNA was quantified by ICP-MS, the effects of cisplatin 
treatment on S. cerevisiae were examined using growth and clonogenic assays combined 
with DAPI and TUNEL staining, and specific platinum binding sites in ribosomes were 
located with mapping experiments. It includes important contributions from Maire F. 
Osborn and Prof. Victoria J. DeRose. I performed the ICP-MS experiments, the growth 
and clonogenic assays, the DAPI and TUNEL staining, and co-wrote the manuscript. 
Maire F. Osborn did the mapping experiments, and co-wrote the manuscript. Prof. 
Victoria J. DeRose guided this project and provided significant editorial feedback. This 
work is in preparation for submission to ACS Chemical Biology. Reproduced with 
permission from ACS Chemical Biology, in preparation. Unpublished work copyright 2011 
American Chemical Society. 
 
Introduction 
Cisplatin (cis-diamminedichloroplatinum(II)) is a potent antitumor agent that has 
had a major clinical impact on the treatment of testicular and ovarian cancers since its 
introduction to the market in 1978. Currently, cisplatin and two other structurally related 
Pt(II) drugs, carboplatin and oxaliplatin, are used in the treatment regimes of 50-70% of 
cancer patients.1 Despite the widespread prescription of cisplatin, a comprehensive 
description of the precise cellular mechanism of its cytotoxicity is still developing. In 
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vivo, cisplatin forms covalent adducts with multiple biomolecule targets including DNA, 
RNA, proteins, and small-molecule ligands.2,3 Drug binding to adjacent purines on 
genomic DNA has been linked to cell cycle arrest at the G2 phase and the induction of 
programmed cell death, a foundation of antitumor activity.4 However, cisplatin treatment 
has also been linked to the disruption of RNA-based processes such as splicing and 
translation.5,6,7 To date, it is unknown if the targeting of non-DNA species by cisplatin, 
especially RNA, may contribute to or sensitize a cell to the downstream effects of this 
drug, including the induction of apoptosis.  
RNA is chemically similar to DNA, but plays functionally diverse roles in cell 
regulation and gene expression. In addition to its well-defined functions in translation 
(mRNA, tRNA, and ribosomes), novel regulatory roles are continuously being defined.8 
These include the discovery of the regulatory roles of siRNA, microRNA, piwi-
interacting RNA, and long noncoding RNAs in both transcription and translation. 
Previously it was thought that RNA damage, whether by free radicals or by anticancer 
agents, only led to RNA degradation. It is now known that RNA damage is an early event 
in the pathogenesis of many diseases and that specific kinds of RNA damage can trigger 
programmed cell death.9-11 Two such examples are sarcin10 and ricin,11 toxic proteins that 
induce apoptosis through their interaction with the sarcin/ricin loop of the large subunit 
of the eukaryotic ribosome. Additionally, there is evidence that both ribosomes and tRNA 
may play specific roles in programmed cell death pathways.12,13  
It is clear that drug binding to RNA has the potential to impact cell fate via 
downstream effects on RNA regulatory pathways. While studies with cisplatin show 
significant in cellulo drug accumulation in RNA as well as inhibition of RNA function in 
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extracts,2,5-7 specific interaction sites have not been previously determined in cellulo in 
eukaryotes. Here we use S. cerevisiae for in cellulo analysis of Pt adduct formation on 
mRNA, rRNA, and total RNA and DNA. S. cerevisiae was chosen as a model because it 
has been used to study a range of anticancer drugs14 and RNA pathways,15,16 and is a 
genetically tractable system for future studies.17 In this study, the action of cisplatin on S. 
cerevisiae in minimal media was established with full growth curves, clonogenic assays, 
and tests for apoptotic markers which determined that while cisplatin treatment is highly 
cytotoxic, under the conditions studied it is not inducing apoptosis. Under defined growth 
conditions, estimates of  in-cell Pt concentrations and the platinum accumulation in 
mRNA, rRNA, total RNA, and DNA were determined using inductively coupled plasma 
mass spectrometry (ICP-MS). Interestingly, while similar Pt accumulation was observed 
in rRNA and total RNA, significantly less accumulated in mRNA. Mapping by reverse 
transcription demonstrates the formation of specific Pt adducts in ribosomes. Taken 
together, these data show both the specificity of Pt adduct formation on RNA following 
in cellulo treatment and important differences in the accumulation of Pt on different RNA 
species.  
 
Cisplatin Treatment Causes Acute Cell Death in S. cerevisiae 
We first sought to establish defined growth conditions for Pt quantification of 
RNA species following cisplatin treatment.  S. cerevisiae has commonly been used as a 
model system for aspects of cisplatin toxicity, including drug transport, DNA repair, and 
the genes involved in drug resistance and sensitivity.18-20 Within these reports, however, 
the sensitivity of S. cerevisiae to cisplatin treatment varies widely. In addition, although 
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cisplatin causes apoptosis in mammalian systems,21 to our knowledge this topic had not 
been addressed for S. cerevisiae despite a growing body of work on yeast apoptotic-like 
cell death pathways.22 Therefore, we characterized cisplatin cytotoxicity in S. cerevisiae 
(strain BY4741) by growth, survival, and tests for apoptotic markers.  
Typically, in human patients cisplatin activation occurs through hydrolysis of the 
labile chloride ligands and is triggered upon moving from relatively high bloodstream Cl- 
concentrations to relatively low intracellular Cl- concentrations.23 For cultured cells, 
however, significant amounts of aquation may take place in the media. In many yeast 
studies with Pt(II) drugs, growth curves have been established from cultures grown in 
YEPD (yeast extract peptone dextrose) or other rich media.24 Under these conditions the 
highly reactive aquation products of cisplatin may interact with soft sulfur- and nitrogen-
containing nucleophiles within the media to effectively sequester the drug, resulting in 
higher IC50 measurements than those observed in mammalian and cancer cell lines (for 
example, 500 µM in S. cerevisiae in YEPD media20 as compared to 2-40 µM for human 
cancer cell lines 25,26,27). To reduce drug sequestering by the media, we assayed drug 
toxicity in minimal SD (synthetic dextrose) liquid media between 1 and 29 h using 100 
µM and 200 µM cisplatin. Full growth curves are shown in Figure 3.1a, demonstrating a 
moderate (76 ± 8% of control at 29 h) and severe (36 ± 1% of the control at 29 h) 
reduction in culture density for 100 µM and 200 µM drug, respectively. 
The effect of cisplatin on BY4741 cells was also monitored through a clonogenic 
assay. Following incubation with cisplatin for 1 to 29 h in minimal media, BY4741 cells 
were plated on drug-free YEPD and colonies were counted following 3 days of growth 
(Figure 3.1b). The results show a marked decrease in cell viability for both cisplatin 
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treatment concentrations, being more rapid and severe for 200 µM cisplatin treatment. 
Although there is a loss of viability after just 1 h of incubation in the drug, the majority of 
irreversible cisplatin toxicity coincides with the onset of exponential growth. From this 
standpoint, we have chosen 6 h (Table 3.1) as a relevant timepoint to investigate the 
distribution of cisplatin-derived Pt species on different RNAs within the cell.  
 
 
Figure 3.1. (a) Exponential growth curves of yeast continuously treated with 0, 100, and 
200 µM cisplatin. Results are averaged from four independent experiments. (b) Survival 
of yeast treated with cisplatin for the indicated time, measured as percentage colony-
forming units (cfu). Results are averaged from three independent experiments.  
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Table 3.1.  Influence of Cisplatin  on S. cerevisiae  at 
6 Hours as Compared to the Control 
Cisplatin Concentration 100 µM 200 µM 
Culture Density 87 ± 6% 71 ± 12% 
Cell Viability 58 ± 5% 27 ± 8% 
 
 
Cisplatin-Induced Cell Death Does Not Proceed Through Apoptosis in BY4741 
Cisplatin induces apoptosis in mammalian cells.21 Cell death via apoptotic 
pathways has been reported for S. cerevisiae when treated with other agents including 
hydrogen peroxide, acetic acid, ethanol, aspirin, arsenic, and anticancer drugs 
(bleomycin, valproate, etc.), however it has not been reported for metallodrugs such as 
cisplatin.22,28 In order to gain more information about toxicity pathways induced by these 
drugs, we assayed cell cultures for hallmarks of apoptosis after continuous treatment with 
cisplatin for 6-12 h. Similar to mammalian systems, yeast apoptosis has been 
demonstrated to result in chromatin condensation and DNA fragmentation.29 DAPI DNA 
staining of BY4741 cells treated with 200 µM cisplatin for 6 h showed significant 
changes in chromatin morphology from the control (Figure 3.2a). In almost all samples, 
nuclei were either fragmented and diffuse, or abnormally enlarged. These findings are 
consistent with an activation of apoptosis, but could be consistent with other forms of 
programmed cell death.30 Interestingly, we were directly able to observe cells undergoing 
cell cycle arrest, a previously observed characteristic of cisplatin treatment in both yeast 
and mammalian systems.31,32 Here, cell cycle arrest is defined by an increase in parent 
cell size in conjunction with an increase in bud size. This is in contrast to the reduction in 
cell size and daughter size at birth that are typically observed for yeast that are 
undergoing slow cell division due to metabolic factors.33 However, it is important to note 
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that oncosis (increase in parent cell volume) is generally associated with necrotic cell 
death,34 with some exceptions.35 
In addition to DAPI staining, apoptotic DNA cleavage is usually assayed through 
terminal dUTP nick-end labeling (TUNEL).29 The reactive 3’-OH species generated by 
apoptosis-induced cleavage are detected by d-UTP labeling with terminal 
deoxynucleotide transferase. Although cell and chromatin morphologies were disrupted, 
BY4741 cells were TUNEL-negative following treatment with 200 µM cisplatin for both 
6 h (Figure 3.2b) and 12 h (data not shown). This suggests that although cisplatin 
treatment may disrupt normal chromatin segregation, it is not sufficient to initiate an 
apoptotic signal culminating in DNA strand breaks in BY4741 under these conditions.  
An apoptotic signal, once triggered, is potentiated through a caspase-like family 
of signaling proteins, including YCA1, which belongs to the type 1 family of 
metacaspases. Yeast apoptosis can also proceed through an independent pathway 
mediated by AIF1, a homolog of mammalian apoptosis-inducing factor.22 To determine if 
cisplatin-induced toxicity proceeds through either of these programmed cell death 
pathways which are involved with the majority of yeast apoptosis29 we assessed the cell 
viability of YCA1 and AIF1 deletion mutants treated with 200 µM cisplatin for 6 h. In 
these cell lines, each disrupted gene was replaced with a KanMX module and tagged with 
a unique primer sequence for identification (Saccharomyces Genome Deletion Project). 
For both YCA1 and AIF1, no differences in cell viability were observed, indicating 
that neither protein is involved in translating drug treatment into downstream cytotoxicity 
in yeast (Figure 3.2c). Based on these results, the cells treated with these specific 
concentrations of cisplatin are likely undergoing a form of necrosis, but whether it is 
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uncontrolled necrosis or a programmed necrosis cannot be determined by the present 
data.34   
A variety of antitumor agents, such as the DNA fragmenting bleomycin, the 
microtubule directed paclitaxel, and the ribosome targeting toxin ricin have been shown 
to induce apoptotic markers in yeast.28,36 There are two main explanations for a lack of 
apoptotic markers upon cisplatin treatment in the current experiments. The first is that 
cisplatin may induce apoptosis in yeast, but not under the conditions studied here. There 
are many cases in the literature in which a stimulus can induce yeast apoptosis at low 
doses and necrosis at high doses.35,37 It is also possible that unlike the case for other 
toxins, yeast lacks a key component of a pathway through which cisplatin treatment 
triggers apoptosis. In mammalian cells the tumor suppressor protein p53 is a central 
player in the induction of apoptosis, but there is no p53 homologue in yeast.18 Mismatch 
repair pathways have been linked to p53-induction of apoptosis in mammalian cell lines, 
but deletion of MMR components in yeast does not influence cisplatin sensitivity.18 Thus, 
in the absence of p53, different cisplatin-induced cell toxicity pathways appear to be 
present in yeast that result in cell cycle arrest and disrupt chromatin morphologies, but 
not the hallmark DNA cleavage events associated with apoptosis. Similar phenotypes 
have been observed in S. cerevisiae following treatment with tunicamycin, an X-type 
agent that also causes cell-cycle arrest and the unfolded protein response, but death by 
non-apoptotic methods.38   
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Figure 3.2. (a) DAPI staining of yeast treated with 0 and 200 µM cisplatin for 6 h. (b) 
TUNEL assay of yeast treated with 0 and 200 µM cisplatin for 6 h. Positive controls were 
obtained by treating fixed, permeabilized cells with 5 U DNase I. (c) Survival of 
BY4741, ΔAif1 and ΔYca1 treated with 200 µM cisplatin for 6 h, measured as percent of 
control colony-forming units (cfu). Inset: average cfu counts for both the control and 
cisplatin treated cultures. Results were averaged from three independent experiments 
presented as the means ± SD. 
 
Cisplatin Treatment Causes an Exponential Increase in the In-Cell Pt 
Concentration 
The concentration of Pt species inside a cell following cisplatin treatment is 
affected by a complex set of dynamics including passive diffusion, active transport into 
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the cell, and active efflux from the cell.23 In order to assess the drug concentrations that 
cellular RNA are exposed to at each timepoint the accumulation of Pt in whole yeast cells 
was measured by ICP-MS. An exponential increase in the amount of Pt per cell was 
observed from 1 to 12 h (Figure B.1, Appendix B), with an estimated 7.0 ± 0.3 × 105  and 
1.2 ± 0.1 × 106 Pt/cell measured at 1 h and 1.7 ± 0.4 × 106 and 3.5 ± 0.2 × 106 Pt/cell 
measured at 6 h for 100 and 200 µM treatment concentrations, respectively. These 
numbers are in line with those measured previously for 130 µM cisplatin-treated yeast at 
18 h39,40 and in cisplatin treated HeLa cells when differences in cell volume are taken into 
account.27,41  
Because cisplatin treatment causes an increase in yeast cell size a clearer picture 
of the in-cell Pt concentration affecting the cellular RNA can be gained by taking the 
volumes of drug treated yeast cells into account. Yeast cell radii were measured from 
differential interference contrast (DIC) images and the volumes were estimated by 
treating the yeast as spheres. Interestingly, the average size of the 200 µM cisplatin-
treated yeast continuously increases, while the average size of the 100 µM cisplatin-
treated yeast remains roughly steady after 6 h, possibly representing differences in the 
viability of the cells in these two cultures at later time points (Figure 3.3a). The average 
volume of the yeast calculated for the control sample is ~ 40 fL, a value consistent with 
other measurements for the volume of a haploid yeast cell.33,42  
Figure 3.3b shows estimated in-cell Pt concentrations using the calculated average 
cell volumes at each treatment concentration. Doubling the cisplatin treatment 
concentration results in a doubling of the measured cellular Pt concentration when it is 
calculated in this manner, with 47 ± 10 and 84 ± 5 µM measured at 6 h for 200 and 100 
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µM respectively. It is worth noting that at 12 h the in-cell Pt concentration is higher than 
the concentration of cisplatin in the media. This effect has been seen before for other 
anticancer metallodrugs43 and is consistent with an active transport process44 and also the 
fact that these drugs produce kinetically inert adducts when bound to cellular targets, 
putting drug binding under kinetic rather than thermodynamic control.45  
 
 
Figure 3.3. (a) Average estimated cell volumes (see Methods). (b) Calculated in-cell Pt 
concentrations based on Pt / cell ICP-MS measurements and the average estimated cell 
volumes. Results were averaged from at least three independent experiments presented as 
the means ± SD. 
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Pt Accumulates to a Different Extent in rRNA, mRNA, Total RNA, and DNA 
In order to elucidate the effect of cisplatin treatment on yeast cellular RNA as a 
whole, ICP-MS was used to quantify the Pt accumulation in total RNA isolated from 100 
and 200 µM cisplatin treated yeast. For both concentrations an exponential increase in Pt 
content was observed from 1 to 12 h (Figure 3.4a), roughly matching the exponential 
increase in Pt cellular concentration. This indicates that accumulation of Pt in RNA is 
roughly proportional to accumulation of Pt in the whole cell. At 6 h the Pt accumulation 
corresponds to one Pt every 14,600 ± 1,500 and 5760 ± 580 nt for 100 and 200 µM 
cisplatin treatments, respectively. As a comparison of target size, the yeast ribosome is 
roughly 5600 nt.46  
Pt accumulation on whole-cell RNA and DNA were tested at 12 h of treatment 
with cisplatin (see Methods). Both cisplatin concentrations yield ~ 3-fold more Pt bound 
to the DNA than the RNA on a per nucleotide basis (Figure 3.4b). However, there is 10-
50 fold more RNA in a yeast cell than DNA,47,48 and so when the whole cell is considered 
there is ~4-20 fold more Pt accumulation in the total cellular RNA than in the total 
cellular DNA (Table 3.2). This result is interesting because cisplatin cellular distribution 
studies done in human cell lines have observed an accumulation of Pt in the nucleus and 
nucleolus.49 The higher per nucleotide Pt accumulation in DNA could be an indication 
that this is taking place.  
In order to compare the Pt accumulation in mRNA and rRNA, total cellular RNA 
was harvested from yeast after 6 h of continuous cisplatin treatment. Messenger RNA 
was extracted with the GenElute mRNA Miniprep Kit from Sigma while 25S and 18S 
rRNA was isolated by gel purification. Pt accumulated in the rRNA and total RNA to a 
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similar extent, while significantly less accumulated in mRNA (Figure 3.4c). Given that 
yeast RNA is 80% ribosomes, 15% tRNA, and 5% mRNA,48 it seems likely that the Pt 
content in the total RNA is largely due to accumulation in rRNA. Assuming a statistical 
distribution of Pt adducts, these data indicate an average of 1 and 2 Pt adducts for every 3 
ribosomes for 6-hr treatments with 100 and 200 µM cisplatin respectively.  
Translation in both yeast and mammalian cells is tightly controlled, and, in 
particular, messenger RNA has a high rate of surveillance.50 In addition, mRNA may take 
on more extended structures than the compact, highly-charged ribosome. Differences in 
structure and protein content are expected to cause each RNA species to present a 
different electrostatic surface to the reactive cationic aquation products of cisplatin. 
Therefore, the lower Pt accumulation in mRNA could be due to either lower initial Pt 
accumulation on mRNA or rapid detection and degradation of Pt-bound mRNAs, or a 
combination of these two effects.  
 
Platinum Accumulation on Ribosomal RNA Is Directly Observed In Cellulo 
The specific location of stable platinum adducts within S. cerevisiae ribosomal 
RNA was probed by 5’ end-labeled primer extension analysis. Reverse transcriptase, as 
well as several other RNA processing enzymes, is directly inhibited by the formation of 
kinetically inert Pt-RNA species.51,52 RT-primer extension can be used to map reactive 
platinum binding sites in cellulo to single nucleotide resolution. Information gained from 
these experiments lends insight into the solvent accessibility and electrostatic potential of 
specific RNA motifs within the ribosome. In addition, we hope to use these data to 
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distinguish platinum adducts whose formation may have downstream consequences from 
those whose accumulation may be more tolerated. 
 
Figure 3.4. (a) Accumulation of Pt atoms in total RNA from yeast treated with cisplatin 
for 1, 3, 6, 9, and 12 h. (b) Accumulation of Pt in total RNA and genomic DNA at 12 h 
on a per nucleotide basis. (c) Accumulation of Pt in mRNA, total RNA, and rRNA at 6 h 
on a per nucleotide basis. Results averaged from at least three independent experiments. 
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Table 3.2.  Number of Pt Atoms Estimated to Accumulate 
in the Total RNA or Genomic DNA of One Yeast Cella 
Cisplatin Concentration 100 µM 200 µM 
DNA (104) 1.5 4.8 
RNA (104) 7-34 24-120 
aCalculations are based on the genome size of S. cerevisiae58, the mass of RNA in one haploid S. cerevisiae 
cell57, and the variance of cellular RNA content over the growth cycle47, treating the mass of RNA 
measured for one haploid cell as a maximum number. 
 
 
Using a similar methodology, Rijal and Chow reported on the locations of 
platinum binding sites within helix 24 of the E. coli small ribosomal subunit.53 Their in 
cellulo results revealed strong cisplatin binding to two adjacent guanines at positions 799 
and 800. Secondary binding was observed at A792, adjacent to a G in the terminal loop 
of helix 24. From these experiments, it was concluded that cisplatin was an effective 
probe for reactive RNA sites that may become targets for de novo antibiotic drug design. 
As an ideal antibiotic drug differentially targets bacterial and eukaryotic ribosomes, we 
became interested in the formation of platinum adducts within this particular helix in S. 
cerevisiae. Importantly, the sequence (helix 18 in yeast) is fully conserved between yeast 
and humans. Reverse transcription experiments were performed on total yeast RNA 
extracted from cultures treated with 0-150 µM cisplatin for 6 h. Under these conditions, 
significant platination occurs at the capping loop of helix 18, as evidenced by two major 
stops in the sequencing gel at positions A792 (***) and A790 (***), as seen in Figure 
3.5. Although it is expected for reverse transcriptase to stop or be stalled at the nucleotide 
3’ to the platinum adduct, the two additional minor stop sites observed occur directly on 
purine residues G797 and G786. Intriguingly, the presence of a C-G wobble base pair at 
position 801 in yeast precludes platinum binding and is sufficient to switch the major stop 
site from position U801 in E. coli to A792 in S. cerevisiae. These findings demonstrate 
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that although aquated cisplatin products are highly reactive, they are remarkably 
sequence-specific.  
The ICP-MS data described above could be used to predict an average coverage 
of approximately one platinum adduct per three ribosomes following treatment with 100 
µM cisplatin over a 6 h time period, but it is reasonable to expect that certain sites will be 
more accessible and/or reactive. The data of Fig. 5 suggest several platination sites near 
helix 18, with an onset at concentrations as low as 50 µM after 6 h. This cluster of targets  
 
Figure 3.5.  Primer extension analysis of RNA isolated from 6 h cisplatin-treated 
BY4741 (left) shows a dosage-dependant increase in termination intensity at indicated 
sites. A dideoxy sequencing ladder is denoted by U, A, G, and C. Major (***) and minor 
(*, **) bands which represent positions adjacent to a platination site are highlighted in the 
secondary structure diagram (right, lower panel) and the crystal structure (right, upper 
panel, PDB 3O30). Experimental results from Rijal and Chow53 are summarized in the E. 
coli secondary structure model (far right, lower panel). The E. coli numbering is used for 
all structures here as a basis of comparison.   
cisplatin (µM) 
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may reflect the solvent accessibility of this loop (Figure B.2, Appendix B). Future studies 
will examine the accumulation of cisplatin-derived reactive species at less accessible sites 
within this macromolecule. 
 
Conclusions 
The action of cisplatin on S. cerevisiae was characterized with full growth curves 
in minimal media and clonogenic assays that assessed cell viability. The majority of 
cisplatin toxicity coincided with the onset of exponential growth, at 6 h. Although DAPI 
staining indicated that the nuclei of some cisplatin treated cells are diffuse and enlarged, 
both the absence of DNA fragmentation (measured by TUNEL staining), and fact that 
YCA1 and AIF1 do not play a role in translating drug treatment into downstream 
cytotoxicity indicate that apoptosis is not taking place under the conditions of this study. 
The amount of Pt per cell increased exponentially from 1 to 12 h. At 6 h the in-cell Pt 
concentrations, calculated using estimated yeast volumes, are 47 ± 10 and 84 ± 5 µM for 
200 and 100 µM respectively. The exponential increase in the Pt accumulation in total 
RNA indicates that the accumulation of Pt in RNA is roughly proportional to 
accumulation of Pt in the whole cell. Comparison of Pt accumulation in RNA and DNA 
at 12 h show ~ 3-fold more Pt bound to the DNA than the RNA on a per nucleotide basis, 
however, taking into account the overabundance of RNA in S. cerevisiae this value 
represents  ~4-20 fold more Pt accumulation in the total cellular RNA than in the total 
cellular DNA. Pt accumulated in the rRNA and total RNA to a similar extent, while 
significantly less accumulated in mRNA. Mapping by reverse transcription demonstrates 
the formation of specific Pt adducts in ribosomes. Taken together, these data show both 
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the specificity of Pt-RNA adduct formation in a eukaryotic cell and important differences 
in the resulting in-cell adducts for specific RNA species. 
 
Materials and Methods 
Cell Cultures and Treatments 
The S. cerevisiae strains used in this study, BY4741 (MATa; his3Δ1; leu2Δ0; 
met15Δ0; ura3Δ0), yca1Δ (BY4741 yca1::kanMX4) and aif1Δ (BY4741 aif1::kanMX4), 
were gifts from the Stevens laboratory at the University of Oregon. All liquid cultures 
were grown on Synthetic Complete medium (SC) consisting of 0.67% yeast nitrogen base 
and 2% glucose as a carbon source supplemented with amino acids and nucleotide bases. 
Plated cells were grown on YEPD agar plates (1% yeast extract, 2% peptone, 2% 
glucose, and 2% agar). Liquid culture growth was maintained in the dark at 30 °C with 
shaking at 200 rpm. A 5 mM cisplatin (Sigma Aldrich) stock in 100 mM NaCl (no more 
than a week old, stored in the dark at room temperature) was used for all yeast treatments. 
Yeast cultures were pregrown to an OD600 of 5 then inoculated into media at 30 °C to an 
OD600 of 0.075 and treated with the given concentrations of cisplatin.  
 
Measurement of Culture Growth, Cell Survival, and Cell Size 
Culture growth was measured as the optical density at 600 nm (conversion factor 
OD600; 1 AU600 = 2.0 × 107 cells/mL). Cell viability was measured by plating serial 
dilutions of treated and untreated yeast onto drug-free YEPD agar plates (~250 
cells/plate) and counting the number of colonies formed after 3 d at 30 °C. The number of 
colony-forming units (cfu) was determined by dividing the cfu counts of treated cultures 
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by those of untreated cultures, which were assumed to be 100%. Yeast cell radii were 
measured from differential interference contrast (DIC) images were obtained on a Carl 
Zeiss Axioplan 2 fluorescence microscope using a 100× objective and AxioVision 
software (Carl Zeiss, Thornwood, NY) and the volumes were calculated by treating the 
yeast as spheres. Data was graphed using SigmaPlot 11.0. 
 
Extraction and Purification of Nucleic Acids 
For measurements of Pt in total RNA ~1.2 × 108 cisplatin treated yeast cells were 
pelleted and RNA was extracted using the MasterPure RNA Purification Kit (Epicentre) 
according to manufacturer’s specifications. For both mRNA and rRNA samples total 
RNA was extracted from cisplatin treated cells (~4 × 108 cells/extraction) according to 
the method of Motorin et al..54 The mRNA was isolated using GenElute mRNA Miniprep 
Kit (Sigma), doing the bind and wash steps twice to ensure maximum mRNA purity. 
Ribosomal RNA was isolated from total RNA run on an 8% denaturing polyacrylamide 
gel. The 25S and 18S bands were visualized by light staining with methylene blue, cut 
out and eluted with an Elutrap Electroelution System (Whatman), then desalted on 3k 
Microsep Centrifugal Devices (Pall). DNA samples were purified from ~2 × 109 cell 
pellets according to the method of Rose et al. including the optional RNase A treatment.55 
All pellets were collected at 4 °C and washed 3 times with deionized H2O before further 
processing. DNA was extracted at 12 h, a time at which it is much easier to obtain a 
suitably pure DNA sample due to the 4-5 fold lower RNA content of the yeast cell.47 
Typically, RNase A treatment is a standard way to ensure DNA purity when DNA is 
extracted at timepoints with higher proportions of RNA, however Pt adducts on RNA are 
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known to inhibit RNase activity,51 and extensive RNase treatment may result in an 
enrichment of Pt content on residual RNA carried through the procedure, thus biasing the 
results. Data was graphed using SigmaPlot 11.0. 
 
Measurement of Pt Content in Whole Cells and Extracted Nucleic Acids 
For whole cell Pt accumulation ~2 × 107 cells were pelleted and washed as 
described above. The RNA and DNA was then desalted on in-house prepared G-25 
sephadex spin columns (BioRad) and quantified by absorbance at 260 nm [extinction 
coefficient]. The whole cell, rRNA, DNA, and some of the total RNA samples were 
digested in 70% nitric acid (trace select, Fluka) for 2 hours at 65oC then diluted to 2% 
(v/v) nitric acid with milli-Q H2O. Pt content was determined by Inductively Coupled 
Plasma Mass Spectrometry (ICP-MS) using a Thermo VG PQExcell quadrupole ICP-MS 
equipped with a Gilson 222 autosampler at the W. M. Keck Collaboratory for Plasma 
Spectrometry (Oregon State University, Corvallis, Oregon). The instrument was 
calibrated , for 194Pt, 195Pt and 196Pt by developing standard curves from a Ru standard 
(High Purity Standards). All measurements were done in triplicate using 115In as an 
internal standard. Data was graphed using SigmaPlot 11.0. 
  
Tests for Apoptotic Markers 
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling 
(TUNEL) was performed according to the method of Madeo et. al.56 with some 
modification. Briefly, 3.0 × 107 yeast cells were pelleted, washed 3x with PBS, fixed with 
3.7% formaldehyde for 2 h at 24 °C, and then digested with 2.5 U zymolyase 100T (US 
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biological) for 30 min at 30 °C in 1 mL sorbitol buffer (1.2 M sorbitiol, 0.5 mM MgCl2, 
35 mM phosphate buffer pH 6.8). A portion of the sample was applied to a polylysine-
coated slide and let dry for 1 hr at 37 °C. The slides were incubated with freshly prepared 
permiabilization solution (0.1% Triton X-100, 0.1 sodium citrate) for 1 min at 4 °C, then 
rinsed 3x with PBS. Positive control samples were incubated with 0.2, 1, and 5 U DNase 
I (Fermentas) for 1 hr at 37 °C in the rxn buffer provided by the manufacturer. Samples 
were incubated with 10 µM TUNEL reaction mixture (in situ cell death detection kit, 
fluorescein, Roche) for 30 min at 37 °C in the dark, rinsed 3x with PBS. Images were 
acquired on a Carl Zeiss Axioplan 2 fluorescence microscope using a 100× objective and 
AxioVision software (Carl Zeiss, Thornwood, NY). DAPI staining was performed by 
pelleting 1.0 × 107 yeast cells, washing 3x with PBS, fixing in 70% EtOH for 30 min at 
room temperature, washing with PBS, and then incubating with 0.5 µg/mL DAPI for 20 
min at room temperature in the dark. The samples were then washed 3x with PBS and 
visualized immediately on the Carl Zeiss Axioplan 2 fluorescence microscope. 
 
5’ End-Labeling 
The DNA primer designed for reverse transcription of helix 18 of the small yeast 
ribosomal subunit was purchased from Integrated DNA Technologies.  -32P 5’ end-
labeling was performed with T4 polynucleotide kinase (Fermentas) according to the 
manufacturer’s protocol. Labeled primer was gel purified by 20% PAGE. Bands were 
visualized using a GE phosphor screen in conjunction with a Molecular Dynamics Storm 
860 imaging system and analyzed with Molecular Dynamics ImageQuant software 
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(version 5.0). The correct bands were excised and eluted overnight in deionized water. 
The resulting eluent was desalted (G25 sephadex) and concentrated by SpeedVac.  
 
Reverse Transcription of Helix 18 of the Small Ribosomal Subunit 
Total RNA extracted from yeast cells treated with cisplatin was used as a template 
for reverse transcription to monitor platination in cellulo. Briefly, a solution of 5 × 106 
cells/mL was grown for 6 h in SD-URA in the presence of 0-300 µM cisplatin. Total 
RNA was isolated using a MasterPure Yeast RNA Extraction kit (Epicentre) and 
resuspended in 10 mM Tris-HCl pH 7.5 and 1mM EDTA pH 7.5 to a final concentration 
of 10 µg/µL. Primer extension analysis was catalyzed by Avian Myeloblastosis Virus 
reverse transcriptase (Fermantas). 1 µg of RNA template was annealed to 100 pmol of the 
specified 5’ end-labeled primer in the manufacturer’s supplied reaction buffer and 
subsequently incubated in the presence of enzyme for 1 hour and 45 minutes at 42C. 
The resulting cDNA products were diluted in loading buffer containing 0.005% (w/v) 
xylene cyanol and bromophenol blue and analyzed by 8% PAGE. Bands were visualized 
as described previously.  
 
Bridge to Chapter IV 
Chapters II and III describe in vitro and in cellulo experiments investigating 
cisplatin-induced RNA platination. The results of these studies motivated us to broaden 
our investigations to other anticancer metallodrugs. The following chapter describes the 
results of a collaboration with Prof. Karen L. McFarlane Holman at Willamette 
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University (Salem, Oregon) in which we performed both in vitro and in cellulo 
investigations of Ru-RNA binding induced by NAMI-A treatment. 
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CHAPTER IV 
RU BINDING TO RNA FOLLOWING TREATMENT WITH THE ANTI-
METASTATIC DRUG NAMI-A IN S. CEREVISIAE AND IN VITRO 
 
This chapter describes in cellulo studies of NAMI-A treated yeast and in vitro 
MALDI-MS experiments comparing binding to RNA and DNA oligonucleotides under 
different solution conditions. It includes important contributions from Michelle L. 
Miranda, Prof. Victoria J. DeRose, and Prof. Karen L. McFarlane Holman. I performed 
the in vitro studies, and wrote the majority of the manuscript. The in cellulo studies were 
done by Michelle L. Miranda under my direction and according to protocols that I 
developed. Michelle L. Miranda also provided an initial draft of the results from the in 
cellulo studies. Both Prof. Victoria J. DeRose and Prof. Karen. L. McFarlane Homan 
provided guidance for this project and contributed significant editorial feedback. 
Reproduced with permission from Biochemistry, submitted for publication. Unpublished 
work copyright 2011 American Chemical Society.    
 
Introduction 
Current metal-based anticancer therapeutics such as cisplatin are effective against 
primary tumors, but suffer from several drawbacks: severe side effects, the development 
of resistance, and only minimal antimetastatic activity.1 Research efforts to find more 
successful treatments have led to a number of promising new drugs. One ruthenium-
based complex has received particular attention and is currently in Phase Two of clinical 
trials: [ImH][trans-RuIIICl4(DMSO)(Im)](Im = imidazole), or NAMI-A (Figure 1.2).2,3 
This complex has shown low toxicity and remarkable efficacy against metastases, 
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especially among lung carcinomas. Multiple effects may be involved in this 
antimetastatic activity, including interactions with the extracellular matrix and the cell 
surface, interference with NO metabolism, effects on tumor metalloproteinases, and 
transport into tumors through binding to serum proteins such as transferrin.4,5 NAMI-A 
also causes transient tumor cell cycle arrest in the premitotic G2/M phase.6 In addition, 
the highly related NAMI, [Na][trans-RuIIICl4(DMSO)(Im)], has been shown to cause a 
marked reduction of tumor nucleic acid content.7 This effect and its consequences have 
not yet been explored for NAMI-A. In short, NAMI-A is an extremely attractive drug 
candidate due to both its antimetastatic activity and low toxicity to healthy cells, but 
much remains to be determined regarding its mechanism of action. 
Redox and ligand exchange chemistry are also considered important to the 
mechanism of action of NAMI-A, and the in vivo effectiveness of aquated and reduced 
drug products have led to the conceptualization of NAMI-A as a prodrug.8 The reduction 
potential of NAMI-A is +0.016 V vs. standard calomel electrode (SCE) in pH 7.4 
phosphate buffer,9 and as such, reduction from Ru(III) to Ru(II) is electrochemically 
attainable by the plasma and cellular reducing agents ascorbate and glutathione. In 
addition to the presence of ubiquitous reducing agents, rapidly dividing cancer cells 
provide a hypoxic environment10,11 accompanied by low pH levels12 that affect reduction 
and subsequent reactivity. Furthermore, several pH-dependent equilibria are possible in 
vivo and, as such, there are expected to be multiple Ru species present, many of which 
have the potential to be therapeutically active.8 
Ru anticancer therapeutics are known to bind to DNA in vitro and in cellulo.13,14 
Indeed, treatment with NAMI-A results in Ru-DNA adducts. Similar to the case of 
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cisplatin, the cytotoxic activity of NAMI-A has been correlated with Ru-DNA 
accumulation in several cancer cell lines.15 Results from in vitro studies using calf 
thymus or plasmid DNA to investigate the consequences of NAMI-A treatment on global 
measures of DNA structure such as thermal denaturation or circular dichroism 
spectroscopic signatures suggest less overall structural effects for NAMI-A than with 
cisplatin, which could be due to the types of adducts formed or less accumulation for a 
given treatment method.16,17 The “soft,” nucleophilic N7 site of guanine is the main site 
of coordination for cisplatin-derived Pt(II), with coordination to the N7 adenine also 
observed.18 Similarly, a hydrolysis product of NAMI-A, [trans-RuCl4(H2O)(Im)]¯, has 
been observed binding to the N7 of 9-methyladenine by NMR.19 Ru-binding to GMP 
following NAMI-A treatment has been documented by capillary electrophoresis coupled 
with inductively coupled plasma mass spectrometry (ICP-MS), and a strong preference 
for guanine over adenine bases was confirmed by electrospray ionization mass 
spectrometry (ESI-MS).20,21 Because of their different propensities for mono- and diaddut 
formation, the in vivo adduct profiles produced by NAMI-A and cisplatin are expected to 
be different. This has been shown in vitro for NAMI, where transcriptional mapping 
combined with denaturing agarose gel electrophoresis was employed to discover that 
fewer intrastrand GG adducts were produced on double stranded DNA.22 A minor 
amount of interstrand cross-links were formed (also fewer than for cisplatin). The other 
adducts formed were most likely monofunctional adducts. To our knowledge the specific 
geometries and percent occurrences of the different DNA adducts formed following 
NAMI-A treatment are not known. 
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RNA is chemically similar to DNA, but plays diverse roles in cell regulation and 
gene expression. In addition to well-known functional roles in translation (mRNA, tRNA, 
and ribosomes) a great deal is now being learned about the regulatory roles carried out by 
RNAs such as siRNA, microRNA, piwi-interacting RNA, and long noncoding RNA in 
both transcription and translation.23 Consistent with these regulatory roles, the integrity of 
cellular RNA is monitored. RNA damage is linked to disease and can trigger 
programmed cell death.24-26 Two such examples are sarcin25 and ricin,26 toxic proteins 
that induce apoptosis through their interaction with the sarcin/ricin loop of the large 
subunit of the eukaryotic ribosome. In addition, there is evidence that both ribosomes and 
tRNA may play specific roles in programmed cell death pathways.27,28  
Drug binding to RNA could impact cell fate via downstream effects on a wide 
range of RNA and regulatory pathways. Studies with cisplatin show significant drug 
accumulation in RNA as well as inhibition of RNA function in extracts.29-31 This could be 
true for other DNA binding drugs such as NAMI-A. To our knowledge, the effect on 
RNA of treatment with NAMI-A has not been previously studied. Here we use S. 
cerevisiae for in cellulo analysis of drug accumulation on RNA, and we perform in vitro 
analysis of binding to RNA and DNA oligonucleotides. S. cerevisiae was chosen as a 
model system because it has been used to study a range of anticancer drugs.32 and RNA 
pathways,33,34 and is a genetically tractable system for future studies.35 When S. 
cerevisiae is treated with NAMI-A, growth inhibition and accumulation of Ru in whole 
cells and cellular RNA is observed. In vitro drug binding occurs with model DNA and 
RNA oligonucleotides. The extent of Ru-nucleotide binding depends on both pH and 
reduction by ascorbate, where enhanced binding occurs under acidic, reducing conditions 
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similar to those found in solid tumors. Taken together, these studies demonstrate the 
binding of NAMI-A or its aquated and reduced derivatives to RNA in vitro and in cellulo, 
and enhanced binding with nucleic acids targets in a tumor-like environment. 
 
Growth Inhibition and Cell Viability Following NAMI-A Treatment  
Yeast in SC media were continuously treated with freshly dissolved NAMI-A for 
1 to 24 h. Concentrations below 100 µM NAMI-A did not result in significant change in 
culture density by 6 h treatment, while treatments of 100-300 µM showed a gradual 
decrease in cell density, making 100 µM a threshold concentration above which 
decreases in culture density are clearly observable (Figure C.1a, Appendix C). Full 
growth curves for 0, 150, and 450 µM NAMI-A are shown in Figure 4.1, demonstrating a 
moderate (63 ± 7% of control at 24 h) and severe (12 ± 3% of the control at 24 h) 
reduction in culture density for 150 and 450 µM, respectively.  
To discriminate between slow and/or reversibly inhibited cell division and full 
loss of cell viability due to NAMI-A treatment, cell survival was measured by clonogenic 
assay. After 6 h of drug treatment, NAMI-A treated yeast were plated on drug-free YEPD 
and allowed to grow for 3 days, at which time the number of resultant colonies were 
compared to the control. The results for four concentrations of NAMI-A ranging from 
150 to 600 µM show a moderate decrease in cell viability that does not scale linearly with 
treatment concentration (Figure 4.1b). Tripling the NAMI-A dose from 150 to 450 µM 
results in a doubling of the number of non-viable cells (viable cells going down from 80 
± 8% to 59 ± 4%) and a somewhat higher loss in cell culture density (from of 88 ± 20% 
to 53 ± 14%, Table 4.1). This relatively low loss of viability contrasts with the properties 
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of the more cytotoxic cisplatin, which after 6 h at a 200 µM treatment concentration 
results in a culture density of 72 ± 14%, but only 27 ± 8% viable cells in comparison with 
controls (Hostetter, Osborn, and DeRose, in preparation). Taken together these results 
indicate that the reduced culture density of NAMI-A treated yeast is due to a combination 
of cell death and slowed growth. Typically yeast that are undergoing slower cell division 
due to general metabolic factors have a smaller average cell size.38 Yeast treated with 
NAMI-A, however, exhibit an increased average cell size (Figure C.1b, Appendix C) 
which might be indicative of cell cycle arrest. 
 
Figure 4.1. (a) Exponential growth curves of yeast treated with 0, 150, and 450 µM 
NAMI-A. (b) Survival of yeast treated for 6 h with NAMI-A measured as percentage 
colony-forming units (cfu) after 3 d in drug-free media. Results were averaged from three 
independent experiments presented as the means ± SD. 
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Accumulation of Ru in Yeast Cells and Cellular RNA 
The Ru content of whole cells and of total RNA isolated from yeast treated for 6 
hrs with 0, 150, and 450 µM NAMI-A were quantified by ICP-MS. Results for both 
whole cells and total RNA show significant Ru accumulation that is proportional to the 
treatment concentration, roughly tripling when the treatment concentration is tripled 
(Figure 4.2). Very approximate average cellular Ru concentrations of ~370 µM and 1200 
 
 
Figure 4.2. (a) Accumulation of Ru atoms per cell in yeast treated with NAMI-A for 6 h. 
(b) Accumulation of Ru atoms in total RNA from yeast treated with NAMI-A for 6 h 
depicted as Ru per nucleotide with the average number of nucleotides per Ru atom given 
in text. Each result was averaged from three independent experiments and presented as 
the mean ± SD. 
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µM (for 150 µM and 450 µM NAMI-A treatment, respectively) can be calculated based 
on these results and estimates for the average volume of growing yeast (see Methods); 
these values are approximate upper limits, since as noted above, yeast cell sizes increase 
with treatment. Although cells were washed in triplicate before analysis, an influence 
from extracellular accumulation of Ru on cell walls cannot be excluded. Nonetheless, the 
proportional increase in Ru content for both whole cells and extracted RNA indicates that 
under these conditions cellular uptake of NAMI-A is not saturated and that Ru 
accumulation in RNA is proportional to the cellular Ru accumulation.  
 
Table 4.1. Effects of NAMI-A on Yeast at 6 Hours 
NAMI-A Concentration 150 µM 450 µM 
Culture Density 88 ± 20% 53 ± 14% 
Cell Viability 80 ± 8% 59 ± 4% 
 
 
Ru Adduct Formation on RNA and DNA Oligonucleotides Following In Vitro 
Treatment with NAMI-A 
Measurements from the in cellulo studies above indicate significant accumulation 
of Ru on cellular RNA following 6 h of NAMI-A exposure in a yeast cell environment. 
To provide context for these results, the reactivity of NAMI-A with RNA and DNA 
oligonucleotides was examined in vitro. NAMI-A was incubated with single-stranded 
RNA and DNA oligonucleotides in an ionic background similar to biological conditions 
(100 mM NaNO3 and 2 mM Mg(NO3)2). Comparative studies were performed at pH 6.0, 
chosen to simulate the lower pH often found in tumor tissue12 and pH 7.4 (blood and 
healthy cells). A strong preference for Ru coordination to G has been previously observed 
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for DNA,21 and so a simple model containing a single GG site embedded in a sequence of 
U or T nucleotides (U6GGU5 and T6GGT5) was chosen for this study.  
Figure 4.3 shows the Matrix-Assisted Laser Desorption/Ionization Time-of-Flight 
(MALDI-TOF) mass spectra following oligonucleotide treatment with NAMI-A for 24 
hrs at pH 6.0. Due to the natural abundances of Ru isotopes, in which there are six 
isotopes that have more than 5% natural abundance (with 101Ru having the highest 
abundance at 31.6%),41 the product peaks appear broad and short. In addition to the 
parent DNA or RNA oligonucleotide ion, the major +1 Ru products are assigned as [oligo 
+ 1Ru] and [oligo + 1Ru(Im)]. Minor peaks for all three +2 Ru product species are also 
present, corresponding to binding at either both Gs or to one G and one U/T. As  
 
Figure 4.3. Representative MALDI-TOF spectra of the products of the incubation of 0, 
150, and 450 µM NAMI-A with 20 µM DNA T6GGT5 or RNA U6GGU5 for 24 h at 37 
°C and pH 6.0 in 100 mM NaNO3 and 2 mM Mg(NO3)2. Filled squares denote 
unmodified, full-length T6GGT5 and U6GGU5 and open squares denote singly depurinated 
oligonucleotides.  
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expected, the relative amount of these +2 Ru products increases with an increase in 
NAMI-A concentration from 150 to 450 µM. No chloride, aqua, hydroxo, or DMSO 
ligands are observed in these mass spectra, indicating loss of all but the least 
exchangeable ligands. This matches previous observations of the loss of labile ligands in 
both ESI and MALDI-TOF mass spectra for other metallodrugs bound to 
oligonucleotides.21,39,42  
In these mass spectra the overall amount of Ru adduct formation appears to be 
similar with RNA and DNA oligonucleotides. MALDI-MS spectra are not quantitative 
due to varying ionization efficiencies, but qualitative conclusions can be drawn from 
similar experiments performed with the same oligonucleotides, ionic conditions, and 
matrix protocols as were used for the data in Figure 4.3. A more exact comparison 
between RNA and DNA products is not possible because the absolute ratio of product to 
starting material may be influenced by differential ionization, and is additionally difficult 
due to the high amount of depurination observed for the DNA oligonucleotide strand. 
Interestingly, the apparent increase in the amount of +Ru product species with 
treatments of 150 to 450 µM NAMI-A is modest, and a comparison of reaction products 
at 6 and 24 h shows that the reaction has run to completion by 6 h (Figures 4.3, 4.4, and 
Figure C.2a, Appendix C). This is surprising as it appears that a significant amount of 
unreacted oligonucleotides remain despite the 7.5 to 22.5-fold excess of NAMI-A. Less 
reaction is observed for A5CCA6 when compared to T6GGT5 in a side-by-side study, 
suggesting that the preference for G previously observed in the literature is observed 
under these conditions as well (Figure C.2b, Appendix C).21 
 
 85 
 
Effects of pH and Ascorbate on Ru-Oligonucleotide Formation Following In Vitro 
Treatment with NAMI-A 
Oligonucleotide reactivity at pH 6.0 (simulation of tumor tissue pH) and pH 7.4 
(blood and healthy cells) were compared and a slight increase of reactivity at lower pH 
was observed (Figure 4.4). The addition of 2.5 mM ascorbate to the reaction, however, 
greatly enhanced the reactivity at both pH values, leading to a nearly complete loss of 
unreacted oligonucleotides, in particular at pH 6.0. Treatment with ascorbate also causes  
 
Figure 4.4. Representative MALDI-TOF spectra of the products of the incubation of 450 
µM NAMI-A with 20 µM DNA T6GGT5 or RNA U6GGU5 at pH 6.0 and 7.4, with and 
without 2.5 mM ascorbate. Reactions were run for 6 h at 37 °C in 100 mM NaNO3 and 2 
mM Mg(NO3)2. Filled squares denote the unmodified, full-length T6GGT5 and U6GGU5 
strands and open squares denote singly depurinated oligonucleotides strands.   
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a change in the observed product species, favoring the inclusion of [oligo + 1Ru(DMSO)] 
and [oligo + 1Ru(DMSO)(Im)], especially at pH 6.0 (Figure 4.4). The changes observed 
upon treatment with ascorbate are consistent with reduction of Ru(III) to Ru(II) leading 
to greater oligonucleotide binding and retention of the DMSO ligand.  
 
Discussion of Ru Accumulation Following NAMI-A Treatment In Cellulo   
Growth, viability, and accumulation of Ru in cells and cellular RNA were 
characterized following treatment with 150 and 450 µM NAMI-A, concentrations that 
produce a moderate and severe reduction in culture density respectively. Based on whole-
cell ICP-MS measurements, growth for 6 hr in these conditions resulted in estimated 
intracellular Ru concentrations of ~370 µM and 1200 M, indicating uptake of Ru from 
the media. As a basis of comparison, in a Phase I clinical trial the mean maximum Ru 
concentration observed in patient blood was 183 ± 17.3 µg/mL (1800 M) for the 
maximum recommended dose (300 mg/m2/day, on day 5, course 1).3 Both the 150 and 
450 µM NAMI-A treatments caused a decrease in the number of viable yeast cells, but 
this loss is modest in comparison with the more cytotoxic cisplatin, indicating that in the 
case of NAMI-A a significant portion of the decreased culture density is due to reversible 
growth inhibition. Indeed, transient cell cycle arrest in human tumor cell lines at the 
G2/M phase has been seen following treatment with NAMI-A.6 The relatively high 
threshold of 100 M NAMI-A that is required to clearly observe decreases in budding 
yeast culture density is consistent with previous observations. For example, a threshold of 
100 M NAMI-A was necessary to cause cell cycle effects in the KB tumor cell line, in 
which a “significant increase of cells in the S and G2/M phases” was observed 24 h after 
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exposure.43 The observed increases in yeast cell size also indicate a halting of the cell 
cycle. Taken together, it is likely that a portion of the reduced culture growth in NAMI-A 
treated budding yeast is due to transient cell cycle arrest.38 
In both total RNA and whole yeast cells Ru accumulated in a dose-dependent 
manner indicating that drug uptake is not saturated at 450 µM and that drug accumulation 
on RNA is proportional to cellular accumulation. This result is consistent with the lack of 
saturation of Ru accumulation observed in human tumor cell lines treated with NAMI-A 
at concentrations up to 600 µM.15 In treated yeast, a significant amount of Ru 
accumulated on RNA: one Ru every 3500 ± 1500 and 1100 ± 550 nucleotides for 150 and 
450 µM NAMI-A, respectively. Assuming that yeast ribosomes, which are 80% of total 
cellular RNA in log-phase growth, accumulate the same amount of Ru as total RNA, 
there would be on average 2 or 5 Ru bound per ribosome.44 RNA binding of this scale has 
the potential to cause significant downstream effects and may be involved in the 
mechanism of cell cycle arrest. A growing body of knowledge connects ribosomal stress 
(such as the disruption of ribosome biogenesis) to p53 activation and cell cycle arrest in 
humans.45 In addition, the elucidation of the nonfunctional rRNA decay pathway in yeast 
is revealing connections between cellular response to RNA damage and DNA damage.46 
To our knowledge this is the first study of both the effect of NAMI-A on the genetically 
tractable S. cerevisiae and the result of NAMI-A treatment on RNA alone. The results 
establish yeast as a model system for studying the effects of NAMI-A on RNA, observing 
a significant level of drug accumulation that has the potential to cause disruption of RNA 
function.  
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Discussion of Ru-Oligonucleotide Adduct Formation Following NAMI-A Treatment 
In Vitro 
When NAMI-A is dissolved in water it undergoes a series of aquation reactions in 
which the chloride, Im, and DMSO ligands can be lost.47,19 The aqua derivates of the 
complex can also be in equilibrium with the hydroxo species, producing a wide range of 
possible active species in solution. The first aquation reaction has been measured to take 
place with a half life of 20 min at pH 7.4 and 2 h at pH 6.0 (25 °C).19 Despite the faster 
aquation at pH 7.4, MALDI-TOF mass spectra showed that both RNA and DNA 
oligonucleotides with a single GG site demonstrated a greater extent of reaction at pH 6.0 
than 7.4 when reacted for 6 h in a physiological salt background. This could be due to the 
greater exchangeability of Ru-aqua ligands as compared to hydroxo ligands, which would 
be expected to form more readily at higher pH, or due to formation of unreactive Ru-
hydroxo polymers at higher pH values.8,19 
The reduction of NAMI-A or its aqua derivatives by ascorbate has been measured 
to take place in seconds at pH 7.4 (37 °C) and significantly increases the rate of 
subsequent aquation reactions.47,48 For the DNA and RNA oligonucleotides examined 
here, the presence of ascorbate caused a significant increase in the extent of reaction 
along with changes in the observed products in the MALDI-TOF mass spectra. Without 
ascorbate, the main observed products had a single bound Ru or Ru(Im). At pH 6.0 the 
ascorbate-treated samples showed mainly a single bound Ru or Ru(DMSO). At pH 7.4 
both Ru(Im) and Ru(DMSO)-bound products were present. The increased resiliency of 
the Ru-DMSO bond following reduction to Ru(II) is likely due to the greater extent of 
d-S backbonding that tends to occur in Ru(II)-DMSO complexes as compared to 
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Ru(III).49 This increased retention of the DMSO ligand as compared to Im is consistent 
with previous studies by Bacac et al.9 and Brindell et al.,48 both of which observed Im 
hydrolysis following reduction of NAMI-A, but to different extents. Our observations 
indicate that ascorbate-induced reduction is taking place and that reduced Ru(II) species 
are binding to the oligonucleotides.49  
In summary, our investigations of the effect of NAMI-A treatment on RNA in 
cellulo and in vitro adds a new piece to the growing understanding of ruthenium-based 
anti-cancer drugs. Firstly, we observe a nonlinear decrease in cell viability in S. 
cerevisiae with increasing NAMI-A concentration that corresponds with a moderate 
decrease in the number of viable cells. We quantified accumulation of Ru within the cells 
and found that hydrolysis products of NAMI-A bind to intracellular RNA in numbers 
large enough to cause 2-5 Ru bound per ribosome. Secondly, to support our in cellulo 
studies, we carried out in vitro treatment of DNA and RNA oligonucleotides with NAMI-
A both in physiological (7.4) and cancer cell (6.0) pH, and in normal and reducing 
environments. The greatest extent of Ru-RNA adduct formation was observed in the 
acidic, reducing environment which is analogous to that of tumor tissue,10-12 giving a 
strong indication that NAMI-A can become activated to react with nucleic acids in the 
environment of a tumor. 
 
Materials and Methods 
Cell Cultures and Treatments 
The S. cerevisiae strain used in this study was BY4741, a gift from the Stevens 
laboratory at the University of Oregon. All liquid cultures were grown on Synthetic 
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Complete medium (SC) consisting of 0.67% yeast nitrogen base and 2% glucose as a 
carbon source supplemented with amino acids and nucleotide bases. Plated cells were 
grown on YEPD agar plates (1% yeast extract, 2% peptone, 2% glucose, and 2% agar). 
Liquid culture growth was maintained in the dark at 30 °C with shaking at 200 rpm. For 
each yeast treatment a 10 mM NAMI-A stock was prepared fresh in 50 mM NaHPO4 (pH 
7.4) with 0.1 M NaCl exactly 10 minutes before the start. Yeast cultures were pregrown 
to an OD600 of 5 then inoculated into media at 30 °C to an OD600 of 0.075 and treated 
with the given concentrations of NAMI-A.  
 
Synthesis and Characterization of NAMI-A  
The two-step procedure described in the international patent held by Mestroni et 
al.36 was followed with slight modifications, as follows. In step two, 0.782 g of 
[(DMSO)2H][trans-RuCl4(DMSO)2] was dissolved in 15 mL of acetone and stirred for 
fifteen minutes to allow the counter ion to dissolve before adding 0.391 g of imidazole. 
The suspension was then heated and stirred at 30 °C for 21 hours. Product was collected 
via vacuum filtration, washing with acetone and ethyl ether and drying under vacuum. 
The final product was recrystallized by dissolving crude NAMI-A in DMSO to form a 
saturated paste, and then acetone was added to precipitate out the product. NAMI-A was 
characterized using FTIR, Raman and UV-Vis spectroscopy. Spectra were in agreement 
with results from samples that were characterized via XRD.37 
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Measurement of Culture Growth and Cell Survival  
Culture growth was measured as the optical density at 600 nm (conversion factor 
OD600; 1 AU600 = 2.0 x 107 cells/mL). Cell viability was measured by plating serial 
dilutions of treated and untreated yeast onto drug-free YEPD agar plates (~200 
cells/plate) and counting the number of colonies formed after 3 d at 30 °C. The number of 
colony-forming units (cfu) was determined by dividing the cfu counts of treated cultures 
by those of untreated cultures, which were assumed to be 100%.  
 
Measurement of Ru Content in Whole Cells and Extracted RNA 
NAMI-A treated yeast cultures were pelleted (6 x 107 cells for whole cell 
measurements and 1.2 x 108 cells for RNA extraction) at 4 °C and washed 3 times with 
milli-Q H2O. RNA was extracted using the MasterPure RNA Purification Kit (Epicentre) 
according to manufacturer’s specifications. The RNA was then desalted on in-house 
prepared G-25 sephadex spin columns (BioRad) and quantified by absorbance at 260 nm 
[extinction coefficient]. Both RNA and whole cell samples were digested in 70% nitric 
acid (trace select, Fluka) for 2 hours at 65oC then diluted to 2% (v/v) nitric acid with 
milli-Q H2O. Ru content was determined by Inductively Coupled Plasma Mass 
Spectrometry (ICP-MS) using a Thermo VG PQExcell quadrupole ICP-MS equipped 
with a Gilson 222 autosampler at the W. M. Keck Collaboratory for Plasma Spectrometry 
(Oregon State University, Corvallis, Oregon). The instrument was calibrated for 99Ru, 
101Ru and 102Ru by developing standard curves from a Ru standard (High Purity 
Standards). All measurements were done in triplicate using 115In as an internal standard. 
Intracellular Ru content was estimated using an average volume of 36.6 fL calculated for 
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a wild-type haploid strain of S. cerevisiae grown on YEPD media,38 whose cell size 
matches estimates for control samples from this study (Figure C.1, Appendix C, and data 
not shown). 
 
In Vitro Oligonucleotide Treatment with NAMI-A  
RNA (Dharmacon, Inc.) and DNA (IDT) oligonucleotides (T6GGT5, U6GGU5, 
and A5CCA6) were heated to 90 °C for 90 s, cooled to room temperature, and then 
incubated with 0, 150, and 450 µM NAMI-A (freshly dissolved in the appropriate buffer 
immediately before use) in 25 mM phosphate buffer (pH 6.0 or 7.4) at 37 °C in the dark. 
All reactions were carried out for 6 or 24 h in 100 mM NaNO3 and 2 mM Mg(NO3)2. 
Ascorbate was freshly dissolved in water immediately before use and added to the 
buffered oligonucleotide samples (final concentration 2.5 mM) immediately before 
NAMI-A. Samples were desalted using in-house prepared G-25 sephadex spin columns 
(BioRad) to stop the reaction. 
 
MALDI-TOF Analysis  
RNA and DNA samples were purified using C18 ZipTips (Millipore) with a 
procedure modified by Champan et al.39 from the manufacturer’s protocol for RNA.40 
ZipTips were washed by aspiration three times with 1:1 MeCN/H2O, and equilibrated by 
washing three times with 0.1% trifluoroacetic acid (TFA). RNAs were bound to the tip by 
repeated aspiration of the analyte solution. Bound RNA was washed three times by 
aspiration with 0.1% TFA, three times with milli-Q water, and then eluted from the 
column using two washes of 1:1 MeCN/H2O. The eluent was dried to completion by 
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SpeedVac and resuspended in a matrix consisting of 375 mM 2’,4’,6’-
trihydroxyacetophenone (THAP, Sigma-Aldrich, puriss. p.a., matrix substance for 
MALDI-MS), 30 mM diammonium citrate in 3:1 EtOH/H2O, with added NH4+ loaded 
Dowex cation exchange beads (Aldrich) and applied to the sample plate. MALDI-MS 
analysis was performed on a Waters QToF Premier mass spectrometer in positive-ion 
mode using V-mode optics. 
 
Bridge to Chapter V 
Chapters II, III, and IV describe in vitro and in cellulo experiments investigating 
cisplatin induced Pt-RNA binding and NAMI-A induced Ru-RNA binding. The 
following chapter pulls this information together in order to compare what has been 
learned about the RNA-binding abilities of the two drugs and discuss future directions for 
research on the interactions of anticancer metallodrugs with RNA. 
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CHAPTER V 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
This chapter pulls together the knowledge gained so far and discusses questions 
for future investigation. All of the writing in this section was done by me, however many 
people have contributed to the ideas herein, including Prof. Victoria J. DeRose, Dr. Erich 
G. Chapman, Maire F. Osborn, and the other members of the DeRose lab.  
 
Introduction 
There is growing knowledge of both the importance RNA processes and the 
connections between RNA and other significant cellular processes such as cell cycle 
control and apoptosis. Despite this, and the fact that antitumor metallodrugs are known to 
bind to nucleic acids, little study has gone into investigating the roles that RNA-binding 
can play in the mechanisms of these and related drugs. This is a gap that the research 
presented in this dissertation addresses through both in vitro and in cellulo studies of the 
effects of cisplatin and NAMI-A treatment on RNA. As discussed in Chapter I cisplatin 
and NAMI-A were chosen because they are two anticancer metallodrugs that are both 
known to bind to DNA and that have different mechanisms of action. The research 
presented here aims to answer basic questions about the reactivity of these drugs (or their 
aquated products) with RNA in vitro and in cellulo, the kinds of adducts that are formed, 
and the types of RNA species that are targeted. Because this is an area of research that is 
largely unexplored every question that is answered leads to at least five new questions to 
explore. As is true for any exciting field full of thought-provoking questions and 
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possibilities, there are far too many questions here for any one person to answer in a 
single dissertation. As such, the following sections discuss both the conclusions drawn so 
far and the questions that these results have opened up for further research, beginning 
with a brief discussion of the relevant properties of cisplatin and NAMI-A.  
 
Cisplatin and NAMI-A 
Cisplatin is the best studied of the anticancer metallodrugs. It is a Pt based drug 
that exerts significant cytotoxicity against a range of primary tumors, and it is believe that 
binding to DNA at the N7 site of purine bases is an important part of its mechanism. 
When inside a cell, the low chloride concentration induces it to undergo aquation of its 
labile chloride ligands, producing aqua species that can react with cellular targets. 
Cisplatin inhibits tumor growth, but has little effect against metastasis.1 
NAMI-A is a promising Ru-based anticancer drug currently in Phase Two of 
clinical trials. It has low general toxicity in patients and a much lower cytotoxicity than 
cisplatin. Rather than being effective against primary tumors, NAMI-A has strong 
antimetastatic effects. Although NAMI-A treatment forms DNA adducts at the N7 of 
purine bases, those adducts cause less structural distortion than those caused by cisplatin 
(likely due to the formation of different types of adducts). Therefore, it is not surprising 
that DNA adduct formation is not believed to be a major part of NAMI-A’s mechanism 
of action. In addition, NAMI-A is known to undergo both aquation and reduction in 
biological conditions.2 
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In Vitro Studies 
Chapter II focused on the in vitro reactions of aquated cisplatin with RNA and 
DNA hairpins, including an RNA hairpin model, termed BBD, containing an internal 
loop that was derived from the active core of the spliceosome. Treatment of BBD with 
aquated cisplatin formed a novel cross-link across this internal loop. Kinetic studies 
determined that both BBD and a completely basepaired RNA hairpin react with aquated 
cisplatin 5-6 fold faster than a DNA hairpin. Interestingly, the rate of these reactions 
increases at lower pH. MALDI-MS analysis demonstrated that for all of these 
oligonucleotide constructs many Pt adducts were forming (as many as 7 [Pt(NH3)2]2+ 
adducts were observed under some conditions). Collectively these data support a model 
in which there are kinetically preferred platinum binding sites, such as the cross-link 
across BBD, that compete with less reactive sites in oligonucleotide structures.  
Chapter IV includes in vitro experiments in which single-stranded RNA and DNA 
oligonucleotides with a simple U6GGU5 or T6GGT5 sequence were treated with NAMI-A 
and then analyzed by MALDI-MS. The results demonstrate significant Ru binding to 
RNA in vitro, which goes to the furthest extent in an acidic, reducing environment like 
that found in a tumor. Although a direct comparison between the reactivity of RNA and 
DNA was not possible, all changes in drug concentration and solution conditions 
produced similar effects on both the RNA and DNA constructs studied, implying that Ru 
binding to RNA and DNA are comparable. 
From these results it is clear that the RNA-binding caused by cisplatin and 
NAMI-A treatment shares some common features: both drugs can cause multiple RNA 
adducts to be formed (even when the simple U6GGU5 was used with NAMI-A), binding 
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is enhanced when the pH is lowered, and similar or better reactivity is observed for RNA 
when compared to DNA. The main difference observed between the cisplatin and NAMI-
A in these studies is that NAMI-A can be activated toward RNA binding through 
reduction, while it is known that cisplatin is not reduced in vivo.  
These comparisons lead to several interesting questions: How do the RNA adduct 
profiles and reaction rates produced by cisplatin and NAMI-A treatment compare? Is 
NAMI-A treatment capable of producing the same type of interstrand cross-link that is 
formed in BBD with cisplatin treatment? It has been shown with DNA that NAMI-A 
treatment causes less structural distortion, possibly due to the formation of a greater 
number of monoadducts.3 Are these differences in adduct profile and structural impact 
true for RNA as well? This is particularly interesting in light of the in cellulo data 
reviewed below that shows that NAMI-A treatment results in greater uptake and higher 
numbers of RNA-adducts while causing lower cytotoxicity. Perhaps there are different 
toxicities for the adducts formed by each drug, in which those produced by NAMI-A 
treatment cause less structural distortion and inhibition of function. This leads to the 
question: What effects do the Ru-RNA adducts produced by NAMI-A treatment have on 
RNA structure and function? This question can be addressed by further in vitro studies, 
beginning with tests of the both ability of Ru to form interstrand cross-links and of exo- 
and endo-nucleases to degrade the Ru-RNA adducts.  
 
In Cellulo Studies in S. Cerevisiae 
Chapter III discussed in cellulo experiments using cisplatin-treated S. cerevisiae. 
At cisplatin treatment concentrations that caused moderate and severe culture growth 
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inhibition at 29 h, large decreases in cell viability were observed at 6 h. Morphological 
studies of cisplatin-treated yeast showed increased cell size and tests for apoptotic 
markers indicated that apoptosis is not taking place. In-cell Pt concentrations and Pt 
accumulation on RNA are roughly proportional when measured by ICP-MS. At 12 h a 
higher Pt per nucleotide ratio was measured in DNA than RNA, but because there is 
much more RNA than DNA per cell, the total number of Pt bound to cellular RNA is 
higher than the total number of Pt bound to cellular DNA for each yeast cell. 
Interestingly, Pt accumulation in gel-isolated rRNA was close to that accumulated in total 
cellular RNA, while the amount of Pt in mRNA was substantially lower.  
Chapter IV covered studies on NAMI-A treated S. cerevisiae. When compared to 
cisplatin, it takes significantly higher doses of NAMI-A to inhibit yeast culture growth. 
At doses that cause both moderate and severe inhibition of culture growth at 24 h, only a 
moderate loss in cell viability was observed at 6 h. This matches literature reports 
indicating that NAMI-A is much less cytotoxic than cisplatin.4 When the Ru 
accumulation in whole cells and cellular RNA was measured by ICP-MS it was found 
that, just as for cisplatin, the accumulation of Ru in RNA is proportional to the 
accumulation of Ru in whole cells. Significantly, it was also observed that more drug 
adducts accumulate per cell for NAMI-A treated yeast than for yeast treated with similar 
concentrations of cisplatin, while causing lower toxicity.  
It is not yet known if different types of cellular RNA accumulate different 
amounts of Ru, nor is it known what type of cell death NAMI-A induces in S. cerevisiae, 
though preliminary studies indicate that apoptosis is not induced (data not shown). These 
interesting lines of investigation lead to several big questions. The first is “Do the adducts 
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formed by cisplatin and NAMI-A treatment accumulate to the same extend in mRNA, 
rRNA, tRNA, and snRNA?” Fundamentally, this question asks both how accessible 
different types of cellular RNA are to metal-based drugs and how the drug-adducts 
formed on those different RNA species are processed. For yeast cultures continuously 
treated with antitumor metallodrugs the processes of accumulation and removal are 
difficult to separate. However, these two important processes could be teased apart by 
studies following the removal of drug adducts from RNA. In these studies, drug treatment 
would be discontinued after a period of time and then the rate of adduct removal for each 
type of RNA could be observed as a function of time. This would tell us if drug adducts 
on mRNA are, in fact, being removed much more quickly than those on rRNA (and thus 
responsible for the differences in observed Pt accumulation). The comparison of adduct 
accumulation and removal between cisplatin and NAMI-A would provide interesting 
information about how general these processes are for different metallodrugs. A related 
research question would be to probe which pathways are responsible for removing Pt and 
Ru adducts using the library of deletion strains available from the Saccharomyces 
Genome Deletion Project to knock out one degradation pathway at a time and observe 
changes in drug adduct accumulation.  
 
Future Possibilities 
There is a great deal still being learned about RNA degradation, repair, and the 
connections between RNA processes, cell cycle control, and apoptosis. In addition, very 
little is known about the effect of anticancer metallodrugs on RNA, leaving numerous 
future research possibilities wide open. Mapping experiments could be done to locate 
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specific drug binding sites in cellular RNAs. All of the in cellulo experiments described 
above would be very interesting to try in HeLa cells, especially if the RNA degradation 
pathways responsible for clearing most of the RNA drug adducts could be first located in 
S. cerevisiae. The contributions of drug adduct formation on RNA to the mechanism of 
action of cisplatin and NAMI-A could be tested using the connections between RNA and 
apoptosis that have been uncovered so far. For example, can cisplatin or NAMI-A treated 
tRNA still bind to cytochrome c and inhibit the initiation of apoptosis?5 In addition, other 
nucleic acid binding anticancer drugs with both similar and different mechanisms of 
action to cisplatin and NAMI-A could be tested to build up both a picture of RNA 
accessibility to metallodrugs and the impacts of drug binding on RNA structure and 
function.  
If I had the time I could easily do five more dissertations on this topic and I 
wouldn’t be anywhere near done answering all of these questions. That is why this is 
such an exciting area of research. It is largely unexplored and full of intriguing questions 
and fascinating possibilities. I am grateful to have had the opportunity to spend my time 
at the University of Oregon exploring it. 
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APPENDIX A 
SUPPORTING INFORMATION FOR CHAPTER II: RAPID CROSS-LINKING 
OF AN RNA INTERNAL LOOP BY THE ANTICANCER DRUG CISPLATIN 
 
Figure A.1. (a) The predicted secondary structure of hybridized SBBD1 and SBBD2 
RNAs with the location of the major platinum induced cross-link on the SBBD1 strand 
highlighted. (b) 20% dPAGE analysis of the products of partial alkali hydrolysis of the 
SBBD cross-link with 5’-end-labeled SBBD1. Lanes: Control- C: 5’ end-labeled SBBD1. 
T1: G specific sequence ladder generated by partial nuclease digestion of SBBD1 RNA 
by T1 RNase. U2: A specific sequence ladder generated by partial nuclease digestion of 
SBBD1 RNA by U2 RNAse. OH-: Reference alkali hydrolysis ladder for SBBD1. SBBD 
Cross-link Samples- C: dPAGE-isolated SBBD cross-link. OH- Lanes: dPAGE-isolated 
SBBD cross-link treated under alkali hydrolysis for increasing amounts of time. 
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Figure A.2. (a) 20% denaturing PAGE analysis of the products of partial alkali 
hydrolysis of the SBBD cross-link with 5’-end-labeled SBBD2. Lanes: Control- C: 5’ 
end-labeled SBBD2. T1: G specific sequence ladder generated by partial nuclease 
digestion of SBBD2 RNA by T1 RNase. U2: A specific sequence ladder generated by 
partial nuclease digestion of SBBD2 RNA by U2 RNAse. OH-: reference alkali 
hydrolysis ladder for SBBD2. SBBD cross-link Samples- C: dPAGE-isolated SBBD2 
cross-link. OH- Lanes: dPAGE-isolated SBBD cross-link treated under alkali hydrolysis 
for increasing amounts of time. (b) The predicted secondary structure of hybridized 
SBBD1 and SBBD2 RNAs with the location of the major [Pt(NH3)2]2+ on the SBBD2 
strand highlighted. 
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Figure A.3. (a) dPAGE radiograms depicting products of cisplatin binding to SBBD in 
pH 6.8 and 7.8 over time. (b) Comparison of the reaction rates of SBBD in pH 6.8 (filled 
circles) and 7.8 (open circles). Conditions: (a) Reactions were performed with 0.1 µM 
SBBD duplex with either 50 µM aquated cisplatin in 5 mM TEA (pH 7.8) or 25 µM 
aquated cisplatin in 5 mM MOPS (pH 6.8). Both reactions were in 100 mM NaNO3, 1 
mM Mg(NO3)2, and at 37 °C. Reactions analyzed by 20% dPAGE. 
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Figure A.4. (a) BBD kinetics with 50 µM (filled circles), 25 µM (open circles), and 12.5 
µM (triangles) aquated cisplatin. (b) Observed rate constant (kobs) versus cisplatin 
concentration. Conditions: Reactions were performed in 100 mM NaNO3, 1 mM 
Mg(NO3)2, and 5 mM TEA (pH 7.8) at 37 °C. 
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Table A.1. Platination Rates of Oligonucleotide Constructsa 
Construct µM Pt pH kobs (10-5 s-1) krxn2 (M-1 s-1)b 
BBD 50 7.8 9.8(1.0) 2.0(2) 
BBD 25 7.8 5.0(3) 2.0(1) 
BBD 12.5 7.8 2.8(3) 2.3(2) 
BBD 25 6.8 21.3(1.8) 8.5(7) 
RNA HP 50 7.8 8.3(2) 1.7(3) 
DNA HP 50 7.8 1.7(2) 0.33(3) 
SBBD 50 7.8 5.2(3) 1.1(1) 
SBBD 25 6.8 17.0(5) 6.8(2) 
a All experiments used 0.1 µM oligonucleotide (or 0.1 M SBBD duplex) and were 
performed at 37 °C with 100 mM NaNO3 and 1 mM Mg(NO3)2. Trials at pH 7.8, and 6.8 
were done in 5 mM TEA and MOPS respectively. 
b Because all kinetics were performed under pseudo-first order conditions, second order 
rate constants were obtained by dividing kobs by the concentration of aquated cisplatin 
used.  
 
 
 
 106 
 
APPENDIX B 
SUPPORTNG INFORMATION FOR CHAPTER III: CHARACTERIZATION OF 
RNA-PT ADDUCTS IN S. CEREVISIAE 
 
 
 
Figure B.1. Accumulation of Pt atoms per yeast cell in yeast treated with cisplatin for 1, 
3, 6, 9, and 12 h. Results averaged from four independent experiments, presented as the 
means ± SD. 
 
 
  
 
 
 
Figure B.2. Helix 18 of the yeast ribosome (green) is located in close proximity to the 
peptidyltransferase center within the small ribosomal subunit (light gray). Image created 
with PyMol from PDB files 3O30 and 3O5H. 
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APPENDIX C 
SUPPORTING INFORMATION FOR CHAPTER IV: RU BINDING TO RNA 
FOLLOWING TREATMENT WITH THE ANTI-METASTATIC DRUG NAMI-A 
IN S. CEREVISIAE AND IN VITRO 
 
Figure C.1. (a) Yeast culture growth after 6 h of continuous NAMI-A treatment. Results 
were averaged from three independent experiments presented as the means ± SD. (b) 
Differential interference contrast images of NAMI-A treated yeast at 6 h.  Images were 
acquired on a Carl Zeiss Axioplan 2 fluorescence microscope using a 100× objective and 
AxioVision software (Carl Zeiss, Thornwood, NY). 
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Figure C.2. Representative MALDI-TOF spectra of the products of the incubation of 
NAMI-A with (a) DNA T6GGT5 for 6 and 24 h in 150 µM NAMI-A and (b) DNA 
T6GGT5 and A5CCA6 for 6 h in 450 µM NAMI-A (comparison of GG and AA binding 
sites). Reactions were run with 20 µM oligonucleotides at pH 6.0  in 100 mM NaNO3 and 
2 mM Mg(NO3)2 at 37 °C. Filled squares denote the unmodified, full-length T6GGT5  and 
A5CCA6 strands and open squares denote singly depurinated oligonucleotides strands.   
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